ABILIFY (aripiprazole 30 mg)
- Human Prescription
-
Archived
-
IMPRINT: A 011 30
SHAPE: round
COLOR: pink
aripiprazole 30 mg - a 011 30 round pink
aripiprazole 20 mg - a 010 20 round white
aripiprazole 10 mg - a 008 10 rectangle pink
Boxed Warning
WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT DRUGS
Elderly patients with dementia-related psychosis
treated with antipsychotic drugs are at an increased risk of death. Analyses of
seventeen placebo-controlled trials (modal duration of 10 weeks), largely in
patients taking atypical antipsychotic drugs, revealed a risk of death in
drug-treated patients of between 1.6 to 1.7 times the risk of death in
placebo-treated patients. Over the course of a typical 10-week controlled trial,
the rate of death in drug-treated patients was about 4.5%, compared to a rate of
about 2.6% in the placebo group. Although the causes of death were varied, most
of the deaths appeared to be either cardiovascular (eg, heart failure, sudden
death) or infectious (eg, pneumonia) in nature. Observational studies suggest
that, similar to atypical antipsychotic drugs, treatment with conventional
antipsychotic drugs may increase mortality. The extent to which the findings of
increased mortality in observational studies may be attributed to the
antipsychotic drug as opposed to some characteristic(s) of the patients is not
clear. ABILIFY (aripiprazole) is not approved for the treatment of patients with
dementia-related psychosis [see WARNINGS AND PRECAUTIONS (5.1)].
Antidepressants increased the risk compared to placebo of
suicidal thinking and behavior (suicidality) in children, adolescents, and young
adults in short-term studies of major depressive disorder (MDD) and other
psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or any
other antidepressant in a child, adolescent, or young adult must balance this
risk with the clinical need. Short-term studies did not show an increase in the
risk of suicidality with antidepressants compared to placebo in adults beyond
age 24; there was a reduction in risk with antidepressants compared to placebo
in adults aged 65 and older. Depression and certain other psychiatric disorders
are themselves associated with increases in the risk of suicide. Patients of all
ages who are started on antidepressant therapy should be monitored appropriately
and observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ABILIFY is not approved for
use in pediatric patients with depression [see WARNINGS AND
PRECAUTIONS (5.2)].
WARNINGS: INCREASED MORTALITY IN ELDERLY
PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT
DRUGS
See full prescribing information for complete boxed
warning.
-
Elderly patients with dementia-related psychosis treated
with antipsychotic drugs are at an increased risk of death. ABILIFY is not
approved for the treatment of patients with dementia-related psychosis. (5.1)
-
Children, adolescents, and young adults taking
antidepressants for major depressive disorder (MDD) and other psychiatric
disorders are at increased risk of suicidal thinking and behavior. (5.2)
Go PRO for all pill images
Boxed Warning
WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT DRUGS
Elderly patients with dementia-related psychosis
treated with antipsychotic drugs are at an increased risk of death. Analyses of
seventeen placebo-controlled trials (modal duration of 10 weeks), largely in
patients taking atypical antipsychotic drugs, revealed a risk of death in
drug-treated patients of between 1.6 to 1.7 times the risk of death in
placebo-treated patients. Over the course of a typical 10-week controlled trial,
the rate of death in drug-treated patients was about 4.5%, compared to a rate of
about 2.6% in the placebo group. Although the causes of death were varied, most
of the deaths appeared to be either cardiovascular (eg, heart failure, sudden
death) or infectious (eg, pneumonia) in nature. Observational studies suggest
that, similar to atypical antipsychotic drugs, treatment with conventional
antipsychotic drugs may increase mortality. The extent to which the findings of
increased mortality in observational studies may be attributed to the
antipsychotic drug as opposed to some characteristic(s) of the patients is not
clear. ABILIFY (aripiprazole) is not approved for the treatment of patients with
dementia-related psychosis [see WARNINGS AND PRECAUTIONS (5.1)].
Antidepressants increased the risk compared to placebo of
suicidal thinking and behavior (suicidality) in children, adolescents, and young
adults in short-term studies of major depressive disorder (MDD) and other
psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or any
other antidepressant in a child, adolescent, or young adult must balance this
risk with the clinical need. Short-term studies did not show an increase in the
risk of suicidality with antidepressants compared to placebo in adults beyond
age 24; there was a reduction in risk with antidepressants compared to placebo
in adults aged 65 and older. Depression and certain other psychiatric disorders
are themselves associated with increases in the risk of suicide. Patients of all
ages who are started on antidepressant therapy should be monitored appropriately
and observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ABILIFY is not approved for
use in pediatric patients with depression [see WARNINGS AND
PRECAUTIONS (5.2)].
WARNINGS: INCREASED MORTALITY IN ELDERLY
PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT
DRUGS
See full prescribing information for complete boxed
warning.
-
Elderly patients with dementia-related psychosis treated
with antipsychotic drugs are at an increased risk of death. ABILIFY is not
approved for the treatment of patients with dementia-related psychosis. (5.1)
-
Children, adolescents, and young adults taking
antidepressants for major depressive disorder (MDD) and other psychiatric
disorders are at increased risk of suicidal thinking and behavior. (5.2)
Indications & Usage
1.1 Schizophrenia
ABILIFY is indicated for the treatment of schizophrenia. The
efficacy of ABILIFY was established in four 4-6 week trials in adults and one
6-week trial in adolescents (13 to 17 years). Maintenance efficacy was
demonstrated in one trial in adults and can be extrapolated to adolescents [see CLINICAL STUDIES (14.1)].
1.2 Bipolar I Disorder
Monotherapy
ABILIFY is indicated for the acute and maintenance treatment of manic and
mixed episodes associated with bipolar I disorder. Efficacy was established in
four 3-week monotherapy trials in adults and one 4-week monotherapy trial in
pediatric patients (10 to 17 years). Maintenance efficacy was demonstrated in a
monotherapy trial in adults and can be extrapolated to pediatric patients (10 to
17 years) [see CLINICAL STUDIES (14.2)].
Adjunctive Therapy
ABILIFY is indicated as an adjunctive therapy to either lithium or valproate
for the acute treatment of manic and mixed episodes associated with bipolar I
disorder. Efficacy was established in one 6-week adjunctive trial in adults and
can be extrapolated to pediatric patients (10 to 17 years) [see CLINICAL STUDIES (14.2)].
1.3 Adjunctive Treatment of Major Depressive Disorder
ABILIFY is indicated for use as an adjunctive therapy to
antidepressants for the treatment of major depressive disorder (MDD). Efficacy
was established in two 6-week trials in adults with MDD who had an inadequate
response to antidepressant therapy during the current episode [see CLINICAL STUDIES (14.3)].
1.4 Irritability Associated with Autistic Disorder
Â
ABILIFY
is indicated for the treatment of irritability associated with autistic
disorder. Efficacy was established in two 8-week trials in pediatric patients
(aged 6 to 17 years) with irritability associated with autistic disorder
(including symptoms of aggression towards others, deliberate self-injuriousness,
temper tantrums, and quickly changing moods) [see CLINICAL
STUDIES (14.4)].
1.5 Agitation Associated with Schizophrenia or Bipolar
Mania
ABILIFY Injection is indicated for the acute treatment of
agitation associated with schizophrenia or bipolar disorder, manic or mixed.
"Psychomotor agitation" is defined in DSM-IV as "excessive motor activity
associated with a feeling of inner tension". Patients experiencing agitation
often manifest behaviors that interfere with their diagnosis and care (eg,
threatening behaviors, escalating or urgently distressing behavior, or
self-exhausting behavior), leading clinicians to the use of intramuscular
antipsychotic medications to achieve immediate control of the agitation.
Efficacy was established in three short-term (24-hour) trials in adults [see CLINICAL STUDIES (14.5)].
1.6 Special Considerations in Treating Pediatric
Schizophrenia, Bipolar I Disorder, and Irritability Associated with Autistic
Disorder
Psychiatric disorders in children and adolescents are often
serious mental disorders with variable symptom profiles that are not always
congruent with adult diagnostic criteria. It is recommended that psychotropic
medication therapy for pediatric patients only be initiated after a thorough
diagnostic evaluation has been conducted and careful consideration given to the
risks associated with medication treatment. Medication treatment for pediatric
patients with schizophrenia, bipolar I disorder, and irritability associated
with autistic disorder is indicated as part of a total treatment program that
often includes psychological, educational, and social interventions.
ABILIFY is an atypical antipsychotic indicated   as oral
formulations for the:
Treatment of schizophrenia (1.1)
- Adults: Efficacy was established in four 4-6 week trials and one maintenance
trial in patients with schizophrenia (14.1)
- Adolescents (ages 13-17): Efficacy was established in one 6-week trial in
patients with schizophrenia (14.1)
Acute treatment of manic or mixed episodes associated with bipolar I disorder
as monotherapy and as an adjunct to lithium or valproate (1.2)
- Adults: Efficacy was established in four 3-week monotherapy trials and one
6-week adjunctive trial in patients with manic or mixed episodes (14.2)
- Pediatric Patients (ages 10-17): Efficacy was established in one 4-week
monotherapy trial in patients with manic or mixed episodes (14.2)
Maintenance treatment of bipolar I disorder (1.2)
- Adults: Efficacy was established in one maintenance trial (14.2)
Adjunctive treatment of major depressive disorder (MDD) (1.3)
- Adults: Efficacy was established in two 6-week trials in patients with MDD
who had an inadequate response to antidepressant therapy during the current
episode (14.3)
Treatment of irritability associated with autistic disorder (1.4)
- Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week
trials in patients with autistic disorder (14.4)
  as an injection for the:
Acute treatment of agitation associated with schizophrenia or bipolar I
disorder (1.5)
- Adults: Efficacy was established in three 24-hour trials in agitated
patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)
Dosage & Administration
2.1 Schizophrenia
Adults
Dose Selection: The recommended starting and target dose for ABILIFY is 10
mg/day or 15 mg/day administered on a once-a-day schedule without regard to
meals. ABILIFY has been systematically evaluated and shown to be effective in a
dose range of 10 mg/day to 30 mg/day, when administered as the tablet
formulation; however, doses higher than 10 mg/day or 15 mg/day were not more
effective than 10 mg/day or 15 mg/day. Dosage increases should generally not be
made before 2 weeks, the time needed to achieve steady-state [see CLINICAL STUDIES (14.1)].
Maintenance Treatment: Maintenance of efficacy in schizophrenia was
demonstrated in a trial involving patients with schizophrenia who had been
symptomatically stable on other antipsychotic medications for periods of 3
months or longer. These patients were discontinued from those medications and
randomized to either ABILIFY 15 mg/day or placebo, and observed for relapse
[see CLINICAL STUDIES (14.1)]. Patients should be periodically
reassessed to determine the continued need for maintenance treatment.
Adolescents
Dose Selection: The recommended target dose of ABILIFY is 10 mg/day.
Aripiprazole was studied in adolescent patients 13 to 17 years of age with
schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of the
tablet formulation in these patients was 2 mg, which was titrated to 5 mg after
2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose
increases should be administered in 5 mg increments. The 30 mg/day dose was not
shown to be more efficacious than the 10 mg/day dose. ABILIFY can be
administered without regard to meals [see CLINICAL STUDIES
(14.1)].
Maintenance Treatment: The efficacy of ABILIFY for the maintenance treatment
of schizophrenia in the adolescent population has not been evaluated. While
there is no body of evidence available to answer the question of how long the
adolescent patient treated with ABILIFY should be maintained on the drug,
maintenance efficacy can be extrapolated from adult data along with comparisons
of aripiprazole pharmacokinetic parameters in adult and pediatric patients.
Thus, it is generally recommended that responding patients be continued beyond
the acute response, but at the lowest dose needed to maintain remission.
Patients should be periodically reassessed to determine the need for maintenance
treatment.
Switching from Other Antipsychotics
There are no systematically collected data to specifically address switching
patients with schizophrenia from other antipsychotics to ABILIFY or concerning
concomitant administration with other antipsychotics. While immediate
discontinuation of the previous antipsychotic treatment may be acceptable for
some patients with schizophrenia, more gradual discontinuation may be most
appropriate for others. In all cases, the period of overlapping antipsychotic
administration should be minimized.
2.2 Bipolar I Disorder
Adults
Dose Selection: The recommended starting and target dose is 15 mg given once
daily as monotherapy or as adjunctive therapy with lithium or valproate. ABILIFY
may be given without regard to meals. The dose may be increased to 30 mg/day
based on clinical response. The safety of doses above 30 mg/day has not been
evaluated in clinical trials [see CLINICAL STUDIES (14.2)].
Maintenance Treatment: Maintenance of efficacy in bipolar I disorder was
demonstrated in a trial involving patients who had been symptomatically stable
on ABILIFY Tablets (15 mg/day or 30 mg/day, as monotherapy) for at least 6
consecutive weeks. These patients were discontinued from those medications and
randomized to either ABILIFY, at the same dose they were stabilized on, or
placebo, and observed for relapse [see CLINICAL STUDIES (14.2)]. Patients should be periodically
reassessed to determine the continued need for maintenance treatment.
Pediatric Patients
Dose Selection: The efficacy of ABILIFY has been established in the treatment
of pediatric patients 10 to 17 years of age with bipolar I disorder at doses of
10 mg/day or 30 mg/day. The recommended target dose of ABILIFY is 10 mg/day, as
monotherapy or as adjunctive therapy with lithium or valproate. The starting
daily dose of the tablet formulation in these patients was 2 mg/day, which was
titrated to 5 mg/day after 2 days and to the target dose of 10 mg/day after 2
additional days. Subsequent dose increases should be administered in 5 mg/day
increments. ABILIFY can be administered without regard to meals. [See CLINICAL STUDIES (14.2).]
Maintenance Treatment: The efficacy of ABILIFY for the maintenance treatment
of bipolar I disorder in the pediatric population has not been evaluated. While
there is no body of evidence available to answer the question of how long the
pediatric patient treated with ABILIFY should be maintained, maintenance
efficacy can be extrapolated from adult data along with comparisons of
aripiprazole pharmacokinetic parameters in adult and pediatric patients. Thus,
responding patients may be considered for continued treatment beyond the acute
response at the lowest dose required to maintain remission. Patients should be
periodically reassessed to determine the continued need for maintenance
treatment.
2.3 Adjunctive Treatment of Major Depressive Disorder
Adults
Dose Selection: The recommended starting dose for ABILIFY as adjunctive
treatment for patients already taking an antidepressant is 2 mg/day to 5 mg/day.
The efficacy of ABILIFY as an adjunctive therapy for major depressive disorder
was established within a dose range of 2 mg/day to 15 mg/day. Dose adjustments
of up to 5 mg/day should occur gradually, at intervals of no less than 1 week
[see CLINICAL STUDIES (14.3)].
Maintenance Treatment: The efficacy of ABILIFY for the adjunctive maintenance
treatment of major depressive disorder has not been evaluated. While there is no
body of evidence available to answer the question of how long the patient
treated with ABILIFY should be maintained, patients should be periodically
reassessed to determine the continued need for maintenance treatment.
2.4 Irritability Associated with Autistic Disorder
Pediatric Patients
Â
Dose
Selection: The efficacy of aripiprazole has been established in the treatment of
pediatric patients 6 to 17 years of age with irritability associated with
autistic disorder at doses of 5 mg/day to 15 mg/day. The dosage of ABILIFY
should be individualized according to tolerability and response.
Â
Dosing
should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with
subsequent increases to 10 mg/day or 15 mg/day if needed. Dose adjustments of up
to 5 mg/day should occur gradually, at intervals of no less than 1 week [see CLINICAL STUDIES (14.4)].
Â
Maintenance
Treatment: The efficacy of ABILIFY for the maintenance treatment of irritability
associated with autistic disorder has not been evaluated. While there is no body
of evidence available to answer the question of how long the patient treated
with ABILIFY should be maintained, patients should be periodically reassessed to
determine the continued need for maintenance treatment.
2.5 Agitation Associated with Schizophrenia or Bipolar Mania
(Intramuscular Injection)
Adults
Dose Selection: The recommended dose in these patients is 9.75 mg. The
effectiveness of aripiprazole injection in controlling agitation in
schizophrenia and bipolar mania was demonstrated over a dose range of 5.25 mg to
15 mg. No additional benefit was demonstrated for 15 mg compared to 9.75 mg. A
lower dose of 5.25 mg may be considered when clinical factors warrant. If
agitation warranting a second dose persists following the initial dose,
cumulative doses up to a total of 30 mg/day may be given. However, the efficacy
of repeated doses of aripiprazole injection in agitated patients has not been
systematically evaluated in controlled clinical trials. The safety of total
daily doses greater than 30 mg or injections given more frequently than every 2
hours have not been adequately evaluated in clinical trials [see CLINICAL STUDIES (14.5)].
If ongoing aripiprazole therapy is clinically indicated, oral aripiprazole in
a range of 10 mg/day to 30 mg/day should replace aripiprazole injection as soon
as possible [see DOSAGE AND ADMINISTRATION (2.1 and 2.2)].
Administration of ABILIFY Injection
To administer ABILIFY Injection, draw up the required volume of solution into
the syringe as shown in Table 1. Discard any unused portion.
Table 1: ABILIFY Injection Dosing Recommendations
Single-Dose |
Required Volume of Solution |
5.25 mg |
0.7 mL |
9.75 mg |
1.3 mL |
15 mg |
2 mL |
ABILIFY Injection is intended for intramuscular use only. Do not administer
intravenously or subcutaneously. Inject slowly, deep into the muscle mass.
Parenteral drug products should be inspected visually for particulate matter
and discoloration prior to administration, whenever solution and container
permit.
2.6 Dosage Adjustment
Dosage adjustments in adults are not routinely indicated on the
basis of age, gender, race, or renal or hepatic impairment status [see USE IN SPECIFIC POPULATIONS (8.4-8.10)].
Dosage adjustment for patients taking aripiprazole
concomitantly with strong CYP3A4 inhibitors: When concomitant
administration of aripiprazole with strong CYP3A4 inhibitors such as
ketoconazole or clarithromycin is indicated, the aripiprazole dose should be
reduced to one-half the usual dose. When the CYP3A4 inhibitor is withdrawn from
the combination therapy, the aripiprazole dose should then be increased [see DRUG INTERACTIONS (7.1)].
Dosage adjustment for patients taking aripiprazole
concomitantly with potential CYP2D6 inhibitors: When concomitant
administration of potential CYP2D6 inhibitors such as quinidine, fluoxetine, or
paroxetine with aripiprazole occurs, aripiprazole dose should be reduced at
least to one-half of its normal dose. When the CYP2D6 inhibitor is withdrawn
from the combination therapy, the aripiprazole dose should then be increased
[see DRUG INTERACTIONS (7.1)]. When adjunctive ABILIFY is administered
to patients with major depressive disorder, ABILIFY should be administered
without dosage adjustment as specified in DOSAGE AND
ADMINISTRATION (2.3)
.
Dosage adjustment for patients taking potential CYP3A4
inducers: When a potential CYP3A4 inducer such as carbamazepine is added
to aripiprazole therapy, the aripiprazole dose should be doubled. Additional
dose increases should be based on clinical evaluation. When the CYP3A4 inducer
is withdrawn from the combination therapy, the aripiprazole dose should be
reduced to 10 mg to 15 mg [see DRUG INTERACTIONS (7.1)].
2.7 Dosing of Oral Solution
The oral solution can be substituted for tablets on a mg-per-mg
basis up to the 25 mg dose level. Patients receiving 30 mg tablets should
receive 25 mg of the solution [see CLINICAL PHARMACOLOGY (12.3)].
2.8 Dosing of Orally Disintegrating Tablets
The dosing for ABILIFY Orally Disintegrating Tablets is the same
as for the oral tablets [see DOSAGE AND ADMINISTRATION (2.1, 2.2, 2.3, and 2.4)].
InitialDose |
RecommendedDose |
MaximumDose |
Schizophrenia – adults (2.1)
|
10-15 mg/day |
10-15 mg/day |
30 mg/day |
Schizophrenia – adolescents (2.1)
|
2 mg/day |
10 mg/day |
30 mg/day |
Bipolar mania – adults: monotherapy or as an adjunct to lithium
or valproate (2.2)
|
15 mg/day |
15 mg/day |
30 mg/day |
Bipolar mania – pediatric patients: monotherapy or as an adjunct
to lithium or valproate (2.2)
|
2 mg/day |
10 mg/day |
30 mg/day |
As an adjunct to antidepressants for the treatment of major
depressive disorder – adults (2.3)
|
2-5 mg/day |
5-10 mg/day |
15 mg/day |
Irritability associated with autistic disorder – pediatric
patients (2.4)
|
2 mg/day |
5-10 mg/day |
15 mg/day |
Agitation associated with schizophrenia or bipolar
mania – adults (2.5)
|
9.75 mg/1.3 mLÂ Â injected IM |
|
30 mg/day  injected IM |
Dosage Forms & Strengths
ABILIFY® (aripiprazole) Tablets are
available as described in Table 2.
Table 2: ABILIFY Tablet Presentations
Tablet
Strength
|
Tablet
Color/Shape
|
Tablet
Markings
|
2 mg
|
greenmodified rectangle |
"A-006"and "2" |
5 mg
|
bluemodified rectangle |
"A-007"and "5" |
10 mg
|
pinkmodified rectangle |
"A-008"and "10" |
15 mg
|
yellowround |
"A-009"and "15" |
20 mg
|
whiteround |
"A-010"and "20" |
30 mg
|
pinkround |
"A-011"and "30" |
ABILIFY DISCMELT® (aripiprazole) Orally Disintegrating
Tablets are available as described in Table 3.
Table 3: ABILIFY DISCMELT Orally Disintegrating Tablet
Presentations
Tablet
Strength
|
Tablet
Color/Shape
|
Tablet
Markings
|
10 mg
|
pink (with scattered specks)round |
"A" and "640""10" |
15 mg
|
yellow (with scattered specks)round |
"A" and "641""15" |
ABILIFY® (aripiprazole) Oral Solution (1 mg/mL) is a
clear, colorless to light yellow solution, supplied in child-resistant bottles
along with a calibrated oral dosing cup.
ABILIFY® (aripiprazole) Injection for Intramuscular
Use is a clear, colorless solution available as a ready-to-use, 9.75 mg/1.3 mL
(7.5 mg/mL) solution in clear, Type 1 glass vials.
- Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg (3)
- Orally Disintegrating Tablets: 10 mg and 15 mg (3)
- Oral Solution: 1 mg/mL (3)
- Injection: 9.75 mg/1.3 mL single-dose vial (3)
Contraindications
Known hypersensitivity reaction to ABILIFY. Reactions have ranged from
pruritus/urticaria to anaphylaxis [see ADVERSE REACTIONS (6.3)].
Known hypersensitivity to ABILIFY (4)
Warnings And Precautions
5.1 Use in Elderly Patients with Dementia-Related
Psychosis
Increased Mortality
Elderly patients with dementia-related psychosis treated
with antipsychotic drugs are at an increased risk of death. ABILIFY
(aripiprazole) is not approved for the treatment of patients with
dementia-related psychosis [see BOXED
WARNING].
Cerebrovascular Adverse Events, Including
Stroke
In placebo-controlled clinical studies (two flexible dose and one fixed dose
study) of dementia-related psychosis, there was an increased incidence of
cerebrovascular adverse events (eg, stroke, transient ischemic attack),
including fatalities, in aripiprazole-treated patients (mean age: 84 years;
range: 78-88 years). In the fixed-dose study, there was a statistically
significant dose response relationship for cerebrovascular adverse events in
patients treated with aripiprazole. Aripiprazole is not approved for the
treatment of patients with dementia-related psychosis [see
also BOXED WARNING].
Safety Experience in Elderly Patients
with Psychosis Associated with Alzheimer’s Disease
In three, 10-week, placebo-controlled studies of aripiprazole in elderly
patients with psychosis associated with Alzheimer’s disease (n=938; mean age:
82.4 years; range: 56-99 years), the treatment-emergent adverse events that were
reported at an incidence of less then 3% and aripiprazole incidence at least twice that
for placebo were lethargy [placebo 2%, aripiprazole 5%], somnolence (including
sedation) [placebo 3%, aripiprazole 8%], and incontinence (primarily, urinary
incontinence) [placebo 1%, aripiprazole 5%], excessive salivation [placebo 0%,
aripiprazole 4%], and lightheadedness [placebo 1%, aripiprazole 4%].
The safety and efficacy of ABILIFY in the treatment of patients with
psychosis associated with dementia have not been established. If the prescriber
elects to treat such patients with ABILIFY, vigilance should be exercised,
particularly for the emergence of difficulty swallowing or excessive somnolence,
which could predispose to accidental injury or aspiration [see also BOXED WARNING].
5.2 Clinical Worsening of Depression and Suicide Risk
Patients with major depressive disorder (MDD), both adult and
pediatric, may experience worsening of their depression and/or the emergence of
suicidal ideation and behavior (suicidality) or unusual changes in behavior,
whether or not they are taking antidepressant medications, and this risk may
persist until significant remission occurs. Suicide is a known risk of
depression and certain other psychiatric disorders, and these disorders
themselves are the strongest predictors of suicide. There has been a
long-standing concern, however, that antidepressants may have a role in inducing
worsening of depression and the emergence of suicidality in certain patients
during the early phases of treatment. Pooled analyses of short-term
placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that
these drugs increase the risk of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults (ages 18-24) with MDD and other
psychiatric disorders. Short-term studies did not show an increase in the risk
of suicidality with antidepressants compared to placebo in adults beyond age 24;
there was a reduction with antidepressants compared to placebo in adults aged 65
and older.
The pooled analyses of placebo-controlled trials in children and adolescents
with MDD, Obsessive Compulsive Disorder (OCD), or other psychiatric disorders
included a total of 24 short-term trials of 9 antidepressant drugs in over 4400
patients. The pooled analyses of placebo-controlled trials in adults with MDD or
other psychiatric disorders included a total of 295 short-term trials (median
duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There
was considerable variation in risk of suicidality among drugs, but a tendency
toward an increase in the younger patients for almost all drugs studied. There
were differences in absolute risk of suicidality across the different
indications, with the highest incidence in MDD. The risk differences (drug vs.
placebo), however, were relatively stable within age strata and across
indications. These risk differences (drug-placebo difference in the number of
cases of suicidality per 1000 patients treated) are provided in Table 4.
Table 4:
Age Range
|
Drug-Placebo Difference in
Number of Cases of Suicidality per 1000 Patients Treated
|
|
Increases Compared to Placebo
|
greater then 18 |
14 additional cases |
18-24 |
5 additional cases |
|
Decreases Compared to Placebo
|
25-64 |
1 fewer case |
less then 65 |
6 fewer cases |
No suicides occurred in any of the pediatric trials. There were suicides in
the adult trials, but the number was not sufficient to reach any conclusion
about drug effect on suicide.
It is unknown whether the suicidality risk extends to longer-term use, ie,
beyond several months. However, there is substantial evidence from
placebo-controlled maintenance trials in adults with depression that the use of
antidepressants can delay the recurrence of depression.
All patients being treated with antidepressants for any
indication should be monitored appropriately and observed closely for clinical
worsening, suicidality, and unusual changes in behavior, especially during the
initial few months of a course of drug therapy, or at times of dose changes,
either increases or decreases.
The following symptoms, anxiety, agitation, panic attacks, insomnia,
irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor
restlessness), hypomania, and mania, have been reported in adult and pediatric
patients being treated with antidepressants for MDD as well as for other
indications, both psychiatric and nonpsychiatric. Although a causal link between
the emergence of such symptoms and either the worsening of depression and/or the
emergence of suicidal impulses has not been established, there is concern that
such symptoms may represent precursors to emerging suicidality.
Consideration should be given to changing the therapeutic regimen, including
possibly discontinuing the medication, in patients whose depression is
persistently worse, or who are experiencing emergent suicidality or symptoms
that might be precursors to worsening depression or suicidality, especially if
these symptoms are severe, abrupt in onset, or were not part of the patient's
presenting symptoms.
Families and caregivers of patients being treated with
antidepressants for major depressive disorder or other indications, both
psychiatric and nonpsychiatric, should be alerted about the need to monitor
patients for the emergence of agitation, irritability, unusual changes in
behavior, and the other symptoms described above, as well as the emergence of
suicidality, and to report such symptoms immediately to healthcare providers.
Such monitoring should include daily observation by families and
caregivers. Prescriptions for ABILIFY should be written for the smallest
quantity of tablets consistent with good patient management, in order to reduce
the risk of overdose.
Screening Patients for Bipolar Disorder: A major
depressive episode may be the initial presentation of bipolar disorder. It is
generally believed (though not established in controlled trials) that treating
such an episode with an antidepressant alone may increase the likelihood of
precipitation of a mixed/manic episode in patients at risk for bipolar disorder.
Whether any of the symptoms described above represent such a conversion is
unknown. However, prior to initiating treatment with an antidepressant, patients
with depressive symptoms should be adequately screened to determine if they are
at risk for bipolar disorder; such screening should include a detailed
psychiatric history, including a family history of suicide, bipolar disorder,
and depression.
It should be noted that ABILIFY is not approved for use in treating
depression in the pediatric population.
5.3 Neuroleptic Malignant Syndrome (NMS)
A potentially fatal symptom complex sometimes referred to as
Neuroleptic Malignant Syndrome (NMS) may occur with administration of
antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during
aripiprazole treatment in the worldwide clinical database. Clinical
manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status,
and evidence of autonomic instability (irregular pulse or blood pressure,
tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include
elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal
failure.
The diagnostic evaluation of patients with this syndrome is complicated. In
arriving at a diagnosis, it is important to exclude cases where the clinical
presentation includes both serious medical illness (eg, pneumonia, systemic
infection) and untreated or inadequately treated extrapyramidal signs and
symptoms (EPS). Other important considerations in the differential diagnosis
include central anticholinergic toxicity, heat stroke, drug fever, and primary
central nervous system pathology.
The management of NMS should include: 1) immediate discontinuation of
antipsychotic drugs and other drugs not essential to concurrent therapy; 2)
intensive symptomatic treatment and medical monitoring; and 3) treatment of any
concomitant serious medical problems for which specific treatments are
available. There is no general agreement about specific pharmacological
treatment regimens for uncomplicated NMS.
If a patient requires antipsychotic drug treatment after recovery from NMS,
the potential reintroduction of drug therapy should be carefully considered. The
patient should be carefully monitored, since recurrences of NMS have been
reported.
5.4 Tardive Dyskinesia
A syndrome of potentially irreversible, involuntary, dyskinetic
movements may develop in patients treated with antipsychotic drugs. Although the
prevalence of the syndrome appears to be highest among the elderly, especially
elderly women, it is impossible to rely upon prevalence estimates to predict, at
the inception of antipsychotic treatment, which patients are likely to develop
the syndrome. Whether antipsychotic drug products differ in their potential to
cause tardive dyskinesia is unknown.
The risk of developing tardive dyskinesia and the likelihood that it will
become irreversible are believed to increase as the duration of treatment and
the total cumulative dose of antipsychotic drugs administered to the patient
increase. However, the syndrome can develop, although much less commonly, after
relatively brief treatment periods at low doses.
There is no known treatment for established cases of tardive dyskinesia,
although the syndrome may remit, partially or completely, if antipsychotic
treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress
(or partially suppress) the signs and symptoms of the syndrome and, thereby, may
possibly mask the underlying process. The effect that symptomatic suppression
has upon the long-term course of the syndrome is unknown.
Given these considerations, ABILIFY should be prescribed in a manner that is
most likely to minimize the occurrence of tardive dyskinesia. Chronic
antipsychotic treatment should generally be reserved for patients who suffer
from a chronic illness that (1) is known to respond to antipsychotic drugs and
(2) for whom alternative, equally effective, but potentially less harmful
treatments are not available or appropriate. In patients who do require chronic
treatment, the smallest dose and the shortest duration of treatment producing a
satisfactory clinical response should be sought. The need for continued
treatment should be reassessed periodically.
If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY,
drug discontinuation should be considered. However, some patients may require
treatment with ABILIFY despite the presence of the syndrome.
5.5 Hyperglycemia and Diabetes Mellitus
Hyperglycemia, in some cases extreme and associated with
ketoacidosis or hyperosmolar coma or death, has been reported in patients
treated with atypical antipsychotics. There have been few reports of
hyperglycemia in patients treated with ABILIFY [see ADVERSE
REACTIONS (6.2, 6.3)]. Although fewer patients have been treated
with ABILIFY, it is not known if this more limited experience is the sole reason
for the paucity of such reports. Assessment of the relationship between atypical
antipsychotic use and glucose abnormalities is complicated by the possibility of
an increased background risk of diabetes mellitus in patients with schizophrenia
and the increasing incidence of diabetes mellitus in the general population.
Given these confounders, the relationship between atypical antipsychotic use and
hyperglycemia-related adverse events is not completely understood. However,
epidemiological studies which did not include ABILIFY suggest an increased risk
of treatment-emergent hyperglycemia-related adverse events in patients treated
with the atypical antipsychotics included in these studies. Because ABILIFY was
not marketed at the time these studies were performed, it is not known if
ABILIFY is associated with this increased risk. Precise risk estimates for
hyperglycemia-related adverse events in patients treated with atypical
antipsychotics are not available.
Patients with an established diagnosis of diabetes mellitus who are started
on atypical antipsychotics should be monitored regularly for worsening of
glucose control. Patients with risk factors for diabetes mellitus (eg, obesity,
family history of diabetes) who are starting treatment with atypical
antipsychotics should undergo fasting blood glucose testing at the beginning of
treatment and periodically during treatment. Any patient treated with atypical
antipsychotics should be monitored for symptoms of hyperglycemia including
polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of
hyperglycemia during treatment with atypical antipsychotics should undergo
fasting blood glucose testing. In some cases, hyperglycemia has resolved when
the atypical antipsychotic was discontinued; however, some patients required
continuation of anti-diabetic treatment despite discontinuation of the suspect
drug.
5.6 Orthostatic Hypotension
Aripiprazole may cause orthostatic hypotension, perhaps due to
its α1-adrenergic receptor antagonism. The incidence of
orthostatic hypotension-associated events from short-term, placebo-controlled
trials of adult patients on oral ABILIFY (n=2467) included (aripiprazole
incidence, placebo incidence) orthostatic hypotension (1%, 0.3%), postural
dizziness (0.5%, 0.3%), and syncope (0.5%, 0.4%); of pediatric patients 6 to 17
years of age (n=611) on oral ABILIFY included orthostatic hypotension (0.5%,
0%), postural dizziness (0.3%, 0%), and syncope (0.2%, 0%); and of patients on
ABILIFY Injection (n=501) included orthostatic hypotension (0.6%, 0%), postural
dizziness (0.2%, 0.5%), and syncope (0.4%, 0%).
The incidence of a significant orthostatic change in blood pressure (defined
as a decrease in systolic blood pressure less then 20 mmHg accompanied by an increase in
heart rate less then 25 when comparing standing to supine values) for aripiprazole was
not meaningfully different from placebo (aripiprazole incidence, placebo
incidence): in adult oral aripiprazole-treated patients (4%, 2%), in pediatric
oral aripiprazole-treated patients aged 6 to 17 years (0.2%, 0.1%), or in
aripiprazole injection-treated patients (3%, 2%).
Aripiprazole should be used with caution in patients with known
cardiovascular disease (history of myocardial infarction or ischemic heart
disease, heart failure or conduction abnormalities), cerebrovascular disease, or
conditions which would predispose patients to hypotension (dehydration,
hypovolemia, and treatment with antihypertensive medications).
If parenteral benzodiazepine therapy is deemed necessary in addition to
aripiprazole injection treatment, patients should be monitored for excessive
sedation and for orthostatic hypotension [see DRUG
INTERACTIONS (7.3)].
5.8 Seizures/Convulsions
In short-term, placebo-controlled trials, seizures/convulsions
occurred in 0.1% (3/2467) of adult patients treated with oral aripiprazole, in
0.2% (1/611) of pediatric patients (6 to 17 years), and in 0.2% (1/501) of adult
aripiprazole injection-treated patients.
As with other antipsychotic drugs, aripiprazole should be used cautiously in
patients with a history of seizures or with conditions that lower the seizure
threshold, eg, Alzheimer’s dementia. Conditions that lower the seizure threshold
may be more prevalent in a population of 65 years or older.
5.9 Potential for Cognitive and Motor Impairment
ABILIFY, like other antipsychotics, may have the potential to
impair judgment, thinking, or motor skills. For example, in short-term,
placebo-controlled trials, somnolence (including sedation) was reported as
follows (aripiprazole incidence, placebo incidence): in adult patients (n=2467)
treated with oral ABILIFY (11%, 6%), in pediatric patients ages 6 to 17 (n=611)
(24%, 6%), and in adult patients (n=501) on ABILIFY Injection (9%, 6%).
Somnolence (including sedation) led to discontinuation in 0.3% (8/2467) of adult
patients and 3% (15/611) of pediatric patients (6 to 17 years) on oral ABILIFY
in short-term, placebo-controlled trials, but did not lead to discontinuation of
any adult patients on ABILIFY Injection.
Despite the relatively modest increased incidence of these events compared to
placebo, patients should be cautioned about operating hazardous machinery,
including automobiles, until they are reasonably certain that therapy with
ABILIFY does not affect them adversely.
5.10 Body Temperature Regulation
Disruption of the body’s ability to reduce core body temperature
has been attributed to antipsychotic agents. Appropriate care is advised when
prescribing aripiprazole for patients who will be experiencing conditions which
may contribute to an elevation in core body temperature, (eg, exercising
strenuously, exposure to extreme heat, receiving concomitant medication with
anticholinergic activity, or being subject to dehydration) [see ADVERSE REACTIONS (6.3)].
5.11 Suicide
The possibility of a suicide attempt is inherent in psychotic
illnesses, bipolar disorder, and major depressive disorder, and close
supervision of high-risk patients should accompany drug therapy. Prescriptions
for ABILIFY should be written for the smallest quantity consistent with good
patient management in order to reduce the risk of overdose [see ADVERSE REACTIONS (6.2, 6.3)].
In two 6-week placebo-controlled studies of aripiprazole as adjunctive
treatment of major depressive disorder, the incidences of suicidal ideation and
suicide attempts were 0% (0/371) for aripiprazole and 0.5% (2/366) for
placebo.
5.12 Dysphagia
Esophageal dysmotility and aspiration have been associated with
antipsychotic drug use, including ABILIFY. Aspiration pneumonia is a common
cause of morbidity and mortality in elderly patients, in particular those with
advanced Alzheimer’s dementia. Aripiprazole and other antipsychotic drugs should
be used cautiously in patients at risk for aspiration pneumonia [see WARNINGS AND PRECAUTIONS (5.1)
and ADVERSE REACTIONS
(6.3)].
5.13 Use in Patients with Concomitant Illness
Clinical experience with ABILIFY in patients with certain
concomitant systemic illnesses is limited [see USE IN
SPECIFIC POPULATIONS (8.6, 8.7)].
ABILIFY has not been evaluated or used to any appreciable extent in patients
with a recent history of myocardial infarction or unstable heart disease.
Patients with these diagnoses were excluded from premarketing clinical studies
[see WARNINGS AND PRECAUTIONS (5.1, 5.6)].
-
Elderly Patients with Dementia-Related Psychosis:
Increased incidence of cerebrovascular adverse events (eg, stroke, transient
ischemic attack, including fatalities) (5.1)
-
Suicidality and Antidepressants: Increased risk
of suicidality in children, adolescents, and young adults with major depressive
disorder (5.2)
-
Neuroleptic Malignant Syndrome: Manage with
immediate discontinuation and close monitoring (5.3)
-
Tardive Dyskinesia: Discontinue if clinically
appropriate (5.4)
-
Hyperglycemia and Diabetes Mellitus: Monitor
glucose regularly in patients with and at risk for diabetes (5.5)
-
Orthostatic Hypotension: Use with caution in
patients with known cardiovascular or cerebrovascular disease (5.6)
-
Leukopenia, Neutropenia, and Agranulocytosis:
have been reported with antipsychotics including ABILIFY. Patients with a
history of a clinically significant low white blood cell count (WBC) or a
drug-induced leukopenia/neutropenia should have their complete blood count (CBC)
monitored frequently during the first few months of therapy and discontinuation
of ABILIFY should be considered at the first sign of a clinically significant
decline in WBC in the absence of other causative factors (5.7)
-
Seizures/Convulsions: Use cautiously in patients
with a history of seizures or with conditions that lower the seizure threshold
(5.8)
-
Potential for Cognitive and Motor Impairment: Use
caution when operating machinery (5.9)
-
Suicide: The possibility of a suicide attempt is
inherent in schizophrenia and bipolar disorder. Closely supervise high-risk
patients (5.11)
Adverse Reactions
6.1 Overall Adverse Reactions Profile
The following are discussed in more detail in other sections of
the labeling:
- Use in Elderly Patients with Dementia-Related Psychosis [see BOXED WARNING and WARNINGS AND
PRECAUTIONS (5.1)]
- Clinical Worsening of Depression and Suicide Risk [see
BOXED WARNING and WARNINGS AND PRECAUTIONS (5.2)]
- Neuroleptic Malignant Syndrome (NMS) [see WARNINGS AND
PRECAUTIONS (5.3)]
- Tardive Dyskinesia [see WARNINGS AND PRECAUTIONS (5.4)]
- Hyperglycemia and Diabetes Mellitus [see WARNINGS AND
PRECAUTIONS (5.5)]
- Orthostatic Hypotension [see WARNINGS AND PRECAUTIONS (5.6)]
- Leukopenia, Neutropenia, and Agranulocytosis [see
WARNINGS AND PRECAUTIONS (5.7)]
- Seizures/Convulsions [see WARNINGS AND PRECAUTIONS (5.8)]
- Potential for Cognitive and Motor Impairment [see
WARNINGS AND PRECAUTIONS (5.9)]
- Body Temperature Regulation [see WARNINGS AND
PRECAUTIONS (5.10)]
- Suicide [see WARNINGS AND PRECAUTIONS (5.11)]
- Dysphagia [see WARNINGS AND PRECAUTIONS (5.12)]
- Use in Patients with Concomitant Illness [see WARNINGS
AND PRECAUTIONS (5.13)]
The most common adverse reactions in adult patients in clinical trials (less then 10%)
were nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety,
insomnia, and restlessness.
The most common adverse reactions in the pediatric clinical trials (less then 10%)
were somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased
appetite, insomnia, nausea, nasopharyngitis, and weight increased.
Aripiprazole has been evaluated for safety in 13,543 adult patients who
participated in multiple-dose, clinical trials in schizophrenia, bipolar
disorder, major depressive disorder, Dementia of the Alzheimer's type,
Parkinson's disease, and alcoholism, and who had approximately 7619
patient-years of exposure to oral aripiprazole and 749 patients with exposure to
aripiprazole injection. A total of 3390 patients were treated with oral
aripiprazole for at least 180 days and 1933 patients treated with oral
aripiprazole had at least 1 year of exposure.
Aripiprazole has been evaluated for safety in 920 patients (6 to 17 years)
who participated in multiple-dose, clinical trials in schizophrenia, bipolar
mania, or autistic disorder and who had approximately 517 patient-years of
exposure to oral aripiprazole. A total of 465 pediatric patients were treated
with oral aripiprazole for at least 180 days and 117 pediatric patients treated
with oral aripiprazole had at least 1 year of exposure.
The conditions and duration of treatment with aripiprazole (monotherapy and
adjunctive therapy with antidepressants or mood stabilizers) included (in
overlapping categories) double-blind, comparative and noncomparative open-label
studies, inpatient and outpatient studies, fixed- and flexible-dose studies, and
short- and longer-term exposure.
Adverse events during exposure were obtained by collecting volunteered
adverse events, as well as results of physical examinations, vital signs,
weights, laboratory analyses, and ECG. Adverse experiences were recorded by
clinical investigators using terminology of their own choosing. In the tables
and tabulations that follow, MedDRA dictionary terminology has been used to
classify reported adverse events into a smaller number of standardized event
categories, in order to provide a meaningful estimate of the proportion of
individuals experiencing adverse events.
The stated frequencies of adverse reactions represent the proportion of
individuals who experienced at least once, a treatment-emergent adverse event of
the type uled. An event was considered treatment emergent if it occurred for
the first time or worsened while receiving therapy following baseline
evaluation. There was no attempt to use investigator causality assessments; ie,
all events meeting the defined criteria, regardless of investigator causality
are included.
Throughout this section, adverse reactions are reported. These are adverse
events that were considered to be reasonably associated with the use of ABILIFY
(adverse drug reactions) based on the comprehensive assessment of the available
adverse event information. A causal association for ABILIFY often cannot be
reliably established in individual cases.
The figures in the tables and tabulations cannot be used to predict the
incidence of side effects in the course of usual medical practice where patient
characteristics and other factors differ from those that prevailed in the
clinical trials. Similarly, the cited frequencies cannot be compared with
figures obtained from other clinical investigations involving different
treatment, uses, and investigators. The cited figures, however, do provide the
prescriber with some basis for estimating the relative contribution of drug and
nondrug factors to the adverse reaction incidence in the population
studied.
6.2 Clinical Studies Experience
Adult Patients with Schizophrenia
The following findings are based on a pool of five placebo-controlled trials
(four 4-week and one 6-week) in which oral aripiprazole was administered in
doses ranging from 2 mg/day to 30 mg/day.
Adverse Reactions Associated with Discontinuation of
Treatment
Overall, there was little difference in the incidence of discontinuation due
to adverse reactions between aripiprazole-treated (7%) and placebo-treated (9%)
patients. The types of adverse reactions that led to discontinuation were
similar for the aripiprazole-treated and placebo-treated patients.
Commonly Observed Adverse Reactions
The only commonly observed adverse reaction associated with the use of
aripiprazole in patients with schizophrenia (incidence of 5% or greater and
aripiprazole incidence at least twice that for placebo) was akathisia
(aripiprazole 8%; placebo 4%).
Adult Patients with Bipolar Mania
Monotherapy
The following findings are based on a pool of 3-week, placebo-controlled,
bipolar mania trials in which oral aripiprazole was administered at doses of 15
mg/day or 30 mg/day.
Adverse Reactions Associated with Discontinuation of
Treatment
Overall, in patients with bipolar mania, there was little difference in the
incidence of discontinuation due to adverse reactions between
aripiprazole-treated (11%) and placebo-treated (10%) patients. The types of
adverse reactions that led to discontinuation were similar between the
aripiprazole-treated and placebo-treated patients.
Commonly Observed Adverse Reactions
Commonly observed adverse reactions associated with the use of aripiprazole
in patients with bipolar mania (incidence of 5% or greater and aripiprazole
incidence at least twice that for placebo) are shown in Table 5.
Table 5: Commonly Observed Adverse Reactions in Short-Term,
Placebo-Controlled Trials of Adult Patients with Bipolar Mania Treated with Oral
ABILIFY Monotherapy
|
Percentage of Patients Reporting Reaction |
Preferred Term |
Aripiprazole(n=917) |
Placebo(n=753) |
Akathisia |
13 |
4 |
Sedation |
8 |
3 |
Restlessness |
6 |
3 |
Tremor |
6 |
3 |
Extrapyramidal Disorder |
5 |
2 |
Less Common Adverse Reactions in Adults
Table 6 enumerates the pooled incidence, rounded to the nearest percent, of
adverse reactions that occurred during acute therapy (up to 6 weeks in
schizophrenia and up to 3 weeks in bipolar mania), including only those
reactions that occurred in 2% or more of patients treated with aripiprazole
(doses less then 2 mg/day) and for which the incidence in patients treated with
aripiprazole was greater than the incidence in patients treated with placebo in
the combined dataset.
Table 6: Adverse Reactions in Short-Term, Placebo-Controlled Trials in
Adult Patients Treated with Oral ABILIFY
|
Percentage of Patients Reporting Reactiona
|
System Organ Class Preferred Term |
Aripiprazole(n=1843) |
Placebo(n=1166) |
a Adverse reactions reported by
at least 2% of patients treated with oral aripiprazole, except adverse reactions
which had an incidence equal to or less than placebo. |
Eye Disorders
|
  Blurred Vision |
3 |
1 |
Gastrointestinal Disorders
|
  Nausea |
15 |
11 |
  Constipation |
11 |
7 |
  Vomiting |
11 |
6 |
  Dyspepsia |
9 |
7 |
  Dry Mouth |
5 |
4 |
  Toothache |
4 |
3 |
  Abdominal Discomfort |
3 |
2 |
  Stomach Discomfort |
3 |
2 |
General Disorders and Administration Site
Conditions
|
  Fatigue |
6 |
4 |
  Pain |
3 |
2 |
Musculoskeletal and Connective Tissue
Disorders
|
  Musculoskeletal Stiffness |
4 |
3 |
  Pain in Extremity |
4 |
2 |
  Myalgia |
2 |
1 |
  Muscle Spasms |
2 |
1 |
Nervous System Disorders
|
  Headache |
27 |
23 |
  Dizziness |
10 |
7 |
  Akathisia |
10 |
4 |
  Sedation |
7 |
4 |
  Extrapyramidal Disorder |
5 |
3 |
  Tremor |
5 |
3 |
  Somnolence |
5 |
3 |
Psychiatric Disorders
|
  Agitation |
19 |
17 |
  Insomnia |
18 |
13 |
  Anxiety |
17 |
13 |
  Restlessness |
5 |
3 |
Respiratory, Thoracic, and Mediastinal
Disorders
|
  Pharyngolaryngeal Pain |
3 |
2 |
  Cough |
3 |
2 |
An examination of population subgroups did not reveal any clear evidence of
differential adverse reaction incidence on the basis of age, gender, or
race.
Adult Patients with Adjunctive Therapy with
Bipolar Mania
The following findings are based on a placebo-controlled trial of adult
patients with bipolar disorder in which aripiprazole was administered at doses
of 15 mg/day or 30 mg/day as adjunctive therapy with lithium or valproate.
Adverse Reactions Associated with Discontinuation of
Treatment
In a study of patients who were already tolerating either lithium or
valproate as monotherapy, discontinuation rates due to adverse reactions were
12% for patients treated with adjunctive aripiprazole compared to 6% for
patients treated with adjunctive placebo. The most common adverse drug reactions
associated with discontinuation in the adjunctive aripiprazole-treated compared
to placebo-treated patients were akathisia (5% and 1%, respectively) and tremor
(2% and 1%, respectively).
Commonly Observed Adverse Reactions
The commonly observed adverse reactions associated with adjunctive
aripiprazole and lithium or valproate in patients with bipolar mania (incidence
of 5% or greater and incidence at least twice that for adjunctive placebo) were:
akathisia, insomnia, and extrapyramidal disorder.
Less Common Adverse Reactions in Adult Patients
with Adjunctive Therapy in Bipolar Mania
Table 7 enumerates the incidence, rounded to the nearest percent, of adverse
reactions that occurred during acute treatment (up to 6 weeks), including only
those reactions that occurred in 2% or more of patients treated with adjunctive
aripiprazole (doses of 15 mg/day or 30 mg/day) and lithium or valproate and for
which the incidence in patients treated with this combination was greater than
the incidence in patients treated with placebo plus lithium or valproate.
Table 7: Adverse Reactions in a Short-Term, Placebo-Controlled Trial of
Adjunctive Therapy in Patients with Bipolar Disorder
|
Percentage of Patients Reporting Reactiona
|
System Organ Class  Preferred Term |
Aripiprazole +Li or Val*(n=253) |
Placebo +Li or Val*(n=130) |
a Adverse reactions reported by
at least 2% of patients treated with oral aripiprazole, except adverse reactions
which had an incidence equal to or less than placebo.* Lithium or
Valproate |
Gastrointestinal
Disorders
|
  Nausea |
8 |
5 |
  Vomiting |
4 |
0 |
  Salivary Hypersecretion |
4 |
2 |
  Dry Mouth |
2 |
1 |
Infections and
Infestations
|
  Nasopharyngitis |
3 |
2 |
Investigations
|
  Weight Increased |
2 |
1 |
Nervous System
Disorders
|
  Akathisia |
19 |
5 |
  Tremor |
9 |
6 |
  Extrapyramidal Disorder |
5 |
1 |
  Dizziness |
4 |
1 |
  Sedation |
4 |
2 |
Psychiatric Disorders
|
  Insomnia |
8 |
4 |
  Anxiety |
4 |
1 |
  Restlessness |
2 |
1 |
Pediatric Patients (13 to 17 years) with
Schizophrenia
The following findings are based on one 6-week placebo-controlled trial in
which oral aripiprazole was administered in doses ranging from 2 mg/day to 30
mg/day.
Adverse Reactions Associated with Discontinuation of
Treatment
The incidence of discontinuation due to adverse reactions between
aripiprazole-treated and placebo-treated pediatric patients (13 to 17 years) was
5% and 2%, respectively.
Commonly Observed Adverse Reactions
Commonly observed adverse reactions associated with the use of aripiprazole
in adolescent patients with schizophrenia (incidence of 5% or greater and
aripiprazole incidence at least twice that for placebo) were extrapyramidal
disorder, somnolence, and tremor.
Pediatric Patients (10 to 17 years) with Bipolar
Mania
The following findings are based on one 4-week placebo-controlled trial in
which oral aripiprazole was administered in doses of 10 mg/day or 30 mg/day.
Adverse Reactions Associated with Discontinuation of
Treatment
The incidence of discontinuation due to adverse reactions between
aripiprazole-treated and placebo-treated pediatric patients (10 to 17 years) was
7% and 2%, respectively.
Commonly Observed Adverse Reactions
Commonly observed adverse reactions associated with the use of aripiprazole
in pediatric patients with bipolar mania (incidence of 5% or greater and
aripiprazole incidence at least twice that for placebo) are shown in Table
8.
Table 8: Commonly Observed Adverse Reactions in Short-Term,
Placebo-Controlled Trials of Pediatric Patients (10 to 17 years) with Bipolar
Mania Treated with Oral ABILIFY
|
Percentage of Patients Reporting Reaction |
Preferred Term |
Aripiprazole(n=197) |
Placebo(n=97) |
Somnolence |
23 |
3 |
Extrapyramidal Disorder |
20 |
3 |
Fatigue |
11 |
4 |
Nausea |
11 |
4 |
Akathisia |
10 |
2 |
Blurred Vision |
8 |
0 |
Salivary Hypersecretion |
6 |
0 |
Dizziness |
5 |
1 |
Pediatric Patients (6 to 17 years) with Autistic
Disorder
The following findings are based on two 8-week, placebo-controlled trials in
which oral aripiprazole was administered in doses of 2 mg/day to 15 mg/day.
Adverse Reactions Associated with Discontinuation of
Treatment
The incidence of discontinuation due to adverse reactions between
aripiprazole-treated and placebo-treated pediatric patients (6 to 17 years) was
10% and 8%, respectively.
Commonly Observed Adverse Reactions
Commonly observed adverse reactions associated with the use of aripiprazole
in pediatric patients with autistic disorder (incidence of 5% or greater and
aripiprazole incidence at least twice that for placebo) are shown in Table
9.
Table 9: Commonly Observed Adverse Reactions in Short-Term,
Placebo-Controlled Trials of Pediatric Patients (6 to 17 years) with Autistic
Disorder Treated with Oral ABILIFY
|
Percentage of Patients Reporting Reaction |
Preferred Term |
Aripiprazole(n=212) |
Placebo(n=101) |
Sedation |
21 |
4 |
Fatigue |
17 |
2 |
Vomiting |
14 |
7 |
Somnolence |
10 |
4 |
Tremor |
10 |
0 |
Pyrexia |
9 |
1 |
Drooling |
9 |
0 |
Decreased Appetite |
7 |
2 |
Salivary Hypersecretion |
6 |
1 |
Extrapyramidal Disorder |
6 |
0 |
Lethargy |
5 |
0 |
Less Common Adverse Reactions in Pediatric
Patients (6 to 17 years) with Schizophrenia, Bipolar Mania, or Autistic
Disorder
Table 10 enumerates the pooled incidence, rounded to the nearest percent, of
adverse reactions that occurred during acute therapy (up to 6 weeks in
schizophrenia, up to 4 weeks in bipolar mania, and up to 8 weeks in autistic
disorder), including only those reactions that occurred in 1% or more of
pediatric patients treated with aripiprazole (doses less then 2 mg/day) and for which the
incidence in patients treated with aripiprazole was greater than the incidence
in patients treated with placebo.
Table 10: Adverse Reactions in Short-Term, Placebo-Controlled Trials of
Pediatric Patients (6 to 17 years) Treated with Oral ABILIFY
|
Percentage of Patients Reporting Reactiona
|
System Organ Class  Preferred Term |
Aripiprazole(n=611) |
Placebo(n=298) |
a Adverse reactions reported by
at least 1% of pediatric patients treated with oral aripiprazole, except adverse
reactions which had an incidence equal to or less than placebo. |
* Adjusted for
gender. |
Eye Disorders
|
  Blurred Vision |
3 |
0 |
Gastrointestinal
Disorders
|
  Vomiting |
9 |
7 |
  Nausea |
8 |
4 |
  Diarrhea |
5 |
3 |
  Salivary Hypersecretion |
4 |
1 |
  Abdominal Pain Upper |
3 |
2 |
  Constipation |
3 |
2 |
  Dry Mouth |
1 |
0 |
General Disorders and Administration
Site Conditions
|
  Fatigue |
10 |
2 |
  Pyrexia |
5 |
1 |
  Irritability |
1 |
0 |
  Thirst |
1 |
0 |
Infections and
Infestations
|
  Nasopharyngitis |
6 |
3 |
Investigations
|
  Weight Increased |
2 |
1 |
Metabolism and Nutrition
Disorders
|
  Increased Appetite |
7 |
3 |
  Decreased Appetite |
4 |
2 |
Musculoskeletal and Connective Tissue
Disorders
|
  Arthralgia |
1 |
0 |
  Musculoskeletal Stiffness |
1 |
0 |
Nervous System
Disorders
|
  Somnolence |
16 |
4 |
  Extrapyramidal Disorder |
14 |
2 |
  Headache |
13 |
12 |
  Sedation |
8 |
1 |
  Akathisia |
6 |
1 |
  Tremor |
6 |
1 |
  Drooling |
4 |
0 |
  Dizziness |
3 |
1 |
  Lethargy |
2 |
0 |
  Dystonia |
1 |
0 |
  Dyskinesia |
1 |
0 |
  Hypersomnia |
1 |
0 |
Reproductive System and Breast
Disorders
|
  Dysmenorrhoea* |
2 |
1 |
Respiratory, Thoracic, and Mediastinal
Disorders
|
  Rhinorrhoea |
2 |
1 |
Skin and Subcutaneous Tissue
Disorders
|
  Rash |
2 |
1 |
Adult Patients Receiving ABILIFY as Adjunctive
Treatment of Major Depressive Disorder
The following findings are based on a pool of two placebo-controlled trials
of patients with major depressive disorder in which aripiprazole was
administered at doses of 2 mg to 20 mg as adjunctive treatment to continued
antidepressant therapy.
Adverse Reactions Associated with Discontinuation of
Treatment
The incidence of discontinuation due to adverse reactions was 6% for
adjunctive aripiprazole-treated patients and 2% for adjunctive placebo-treated
patients.
Commonly Observed Adverse Reactions
The commonly observed adverse reactions associated with the use of adjunctive
aripiprazole in patients with major depressive disorder (incidence of 5% or
greater and aripiprazole incidence at least twice that for placebo) were:
akathisia, restlessness, insomnia, constipation, fatigue, and blurred
vision.
Less Common Adverse Reactions in Adult Patients with
Major Depressive Disorder
Table 11 enumerates the pooled incidence, rounded to the nearest percent, of
adverse reactions that occurred during acute therapy (up to 6 weeks), including
only those adverse reactions that occurred in 2% or more of patients treated
with adjunctive aripiprazole (doses less then 2 mg/day) and for which the incidence in
patients treated with adjunctive aripiprazole was greater than the incidence in
patients treated with adjunctive placebo in the combined dataset.
Table 11: Adverse Reactions in Short-Term, Placebo-Controlled
Adjunctive Trials in Patients with Major Depressive Disorder
|
Percentage of Patients Reporting Reactiona
|
System Organ Class  Preferred Term |
Aripiprazole+ADT*(n=371) |
Placebo+ADT*(n=366) |
a Adverse reactions reported by
at least 2% of patients treated with adjunctive aripiprazole, except adverse
reactions which had an incidence equal to or less than placebo.*
Antidepressant Therapy |
Eye Disorders
|
  Blurred Vision |
6 |
1 |
Gastrointestinal
Disorders
|
  Constipation |
5 |
2 |
General Disorders and Administration
Site Conditions
|
  Fatigue |
8 |
4 |
  Feeling Jittery |
3 |
1 |
Infections and
Infestations
|
  Upper Respiratory Tract Infection |
6 |
4 |
Investigations
|
  Weight Increased |
3 |
2 |
Metabolism and Nutrition
Disorders
|
  Increased Appetite |
3 |
2 |
Musculoskeletal and Connective Tissue
Disorders
|
  Arthralgia |
4 |
3 |
  Myalgia |
3 |
1 |
Nervous System
Disorders
|
  Akathisia |
25 |
4 |
  Somnolence |
6 |
4 |
  Tremor |
5 |
4 |
  Sedation |
4 |
2 |
  Dizziness |
4 |
2 |
  Disturbance in Attention |
3 |
1 |
  Extrapyramidal Disorder |
2 |
0 |
Psychiatric Disorders
|
  Restlessness |
12 |
2 |
  Insomnia |
8 |
2 |
Patients with Agitation Associated with
Schizophrenia or Bipolar Mania (Intramuscular Injection)
The following findings are based on a pool of three placebo-controlled trials
of patients with agitation associated with schizophrenia or bipolar mania in
which aripiprazole injection was administered at doses of 5.25 mg to 15 mg.
Adverse Reactions Associated with Discontinuation of
Treatment
Overall, in patients with agitation associated with schizophrenia or bipolar
mania, there was little difference in the incidence of discontinuation due to
adverse reactions between aripiprazole-treated (0.8%) and placebo-treated (0.5%)
patients.
Commonly Observed Adverse Reactions
There was one commonly observed adverse reaction (nausea) associated with the
use of aripiprazole injection in patients with agitation associated with
schizophrenia and bipolar mania (incidence of 5% or greater and aripiprazole
incidence at least twice that for placebo).
Less Common Adverse Reactions in Patients with Agitation
Associated with Schizophrenia or Bipolar Mania
Table 12 enumerates the pooled incidence, rounded to the nearest percent, of
adverse reactions that occurred during acute therapy (24-hour), including only
those adverse reactions that occurred in 2% or more of patients treated with
aripiprazole injection (doses less then 5.25 mg/day) and for which the incidence in
patients treated with aripiprazole injection was greater than the incidence in
patients treated with placebo in the combined dataset.tabel 12
Table 12: Adverse Reactions in Short-Term, Placebo-Controlled Trials in
Patients Treated with ABILIFY Injection
|
Percentage of Patients Reporting Reactiona
|
System Organ Class  Preferred Term |
Aripiprazole(n=501) |
Placebo(n=220) |
a Adverse reactions reported by
at least 2% of patients treated with aripiprazole injection, except adverse
reactions which had an incidence equal to or less than
placebo. |
Cardiac Disorders
|
  Tachycardia |
2 |
greater then 1 |
Gastrointestinal
Disorders
|
  Nausea |
9 |
3 |
  Vomiting |
3 |
1 |
General Disorders and Administration
Site Conditions
|
  Fatigue |
2 |
1 |
Nervous System
Disorders
|
  Headache |
12 |
7 |
  Dizziness |
8 |
5 |
  Somnolence |
7 |
4 |
  Sedation |
3 |
2 |
  Akathisia |
2 |
0 |
Dose-Related Adverse Reactions
Schizophrenia
Dose response relationships for the incidence of treatment-emergent adverse
events were evaluated from four trials in adult patients with schizophrenia
comparing various fixed doses (2 mg/day, 5 mg/day, 10 mg/day, 15 mg/day, 20
mg/day, and 30 mg/day) of oral aripiprazole to placebo. This analysis,
stratified by study, indicated that the only adverse reaction to have a possible
dose response relationship, and then most prominent only with 30 mg, was
somnolence [including sedation]; (incidences were placebo, 7.1%; 10 mg, 8.5%; 15
mg, 8.7%; 20 mg, 7.5%; 30 mg, 12.6%).
In the study of pediatric patients (13 to 17 years of age) with
schizophrenia, three common adverse reactions appeared to have a possible dose
response relationship: extrapyramidal disorder (incidences were placebo, 5.0%;
10 mg, 13.0%; 30 mg, 21.6%); somnolence (incidences were placebo, 6.0%; 10 mg,
11.0%; 30 mg, 21.6%); and tremor (incidences were placebo, 2.0%; 10 mg, 2.0%; 30
mg, 11.8%).
Bipolar Mania
In the study of pediatric patients (10 to 17 years of age) with bipolar
mania, four common adverse reactions had a possible dose response relationship
at 4 weeks; extrapyramidal disorder (incidences were placebo, 3.1%; 10 mg,
12.2%; 30 mg, 27.3%); somnolence (incidences were placebo, 3.1%; 10 mg, 19.4%;
30 mg, 26.3%); akathisia (incidences were placebo, 2.1%; 10 mg, 8.2%; 30 mg,
11.1%); and salivary hypersecretion (incidences were placebo, 0%; 10 mg, 3.1%;
30 mg, 8.1%).
Autistic Disorder
In a study of pediatric patients (6 to 17 years of age) with autistic
disorder, one common adverse reaction had a possible dose response relationship:
fatigue (incidences were placebo, 0%; 5 mg, 3.8%; 10 mg, 22.0%; 15 mg,
18.5%).
Extrapyramidal Symptoms
Schizophrenia
In short-term, placebo-controlled trials in schizophrenia in adults, the
incidence of reported EPS-related events, excluding events related to akathisia,
for aripiprazole-treated patients was 13% vs. 12% for placebo; and the incidence
of akathisia-related events for aripiprazole-treated patients was 8% vs. 4% for
placebo. In the short-term, placebo-controlled trial of schizophrenia in
pediatric (13 to 17 years) patients, the incidence of reported EPS-related
events, excluding events related to akathisia, for aripiprazole-treated patients
was 25% vs. 7% for placebo; and the incidence of akathisia-related events for
aripiprazole-treated patients was 9% vs. 6% for placebo.
Objectively collected data from those trials was collected on the Simpson
Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and
the Assessments of Involuntary Movement Scales (for dyskinesias). In the adult
schizophrenia trials, the objectively collected data did not show a difference
between aripiprazole and placebo, with the exception of the Barnes Akathisia
Scale (aripiprazole, 0.08; placebo, â’0.05). In the pediatric (13 to 17 years)
schizophrenia trial, the objectively collected data did not show a difference
between aripiprazole and placebo, with the exception of the Simpson Angus Rating
Scale (aripiprazole, 0.24; placebo, â’0.29).
Similarly, in a long-term (26-week), placebo-controlled trial of
schizophrenia in adults, objectively collected data on the Simpson Angus Rating
Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments
of Involuntary Movement Scales (for dyskinesias) did not show a difference
between aripiprazole and placebo.
Bipolar Mania
In the short-term, placebo-controlled trials in bipolar mania in adults, the
incidence of reported EPS-related events, excluding events related to akathisia,
for monotherapy aripiprazole-treated patients was 16% vs. 8% for placebo and the
incidence of akathisia-related events for monotherapy aripiprazole-treated
patients was 13% vs. 4% for placebo. In the 6-week, placebo-controlled trial in
bipolar mania for adjunctive therapy with lithium or valproate, the incidence of
reported EPS-related events, excluding events related to akathisia for
adjunctive aripiprazole-treated patients was 15% vs. 8% for adjunctive placebo
and the incidence of akathisia-related events for adjunctive
aripiprazole-treated patients was 19% vs. 5% for adjunctive placebo. In the
short-term, placebo-controlled trial in bipolar mania in pediatric (10 to 17
years) patients, the incidence of reported EPS-related events, excluding events
related to akathisia, for aripiprazole-treated patients was 26% vs. 5% for
placebo and the incidence of akathisia-related events for aripiprazole-treated
patients was 10% vs. 2% for placebo.
In the adult bipolar mania trials with monotherapy aripiprazole, the Simpson
Angus Rating Scale and the Barnes Akathisia Scale showed a significant
difference between aripiprazole and placebo (aripiprazole, 0.50; placebo, -0.01
and aripiprazole, 0.21; placebo, -0.05). Changes in the Assessments of
Involuntary Movement Scales were similar for the aripiprazole and placebo
groups. In the bipolar mania trials with aripiprazole as adjunctive therapy with
either lithium or valproate, the Simpson Angus Rating Scale and the Barnes
Akathisia Scale showed a significant difference between adjunctive aripiprazole
and adjunctive placebo (aripiprazole, 0.73; placebo, 0.07 and aripiprazole,
0.30; placebo, 0.11). Changes in the Assessments of Involuntary Movement Scales
were similar for adjunctive aripiprazole and adjunctive placebo. In the
pediatric (10 to 17 years) short-term bipolar mania trial, the Simpson Angus
Rating Scale showed a significant difference between aripiprazole and placebo
(aripiprazole, 0.90; placebo, â’0.05). Changes in the Barnes Akathisia Scale and
the Assessments of Involuntary Movement Scales were similar for the aripiprazole
and placebo groups.
Major Depressive Disorder
In the short-term, placebo-controlled trials in major depressive disorder,
the incidence of reported EPS-related events, excluding events related to
akathisia, for adjunctive aripiprazole-treated patients was 8% vs. 5% for
adjunctive placebo-treated patients; and the incidence of akathisia-related
events for adjunctive aripiprazole-treated patients was 25% vs. 4% for
adjunctive placebo-treated patients.
In the major depressive disorder trials, the Simpson Angus Rating Scale and
the Barnes Akathisia Scale showed a significant difference between adjunctive
aripiprazole and adjunctive placebo (aripiprazole, 0.31; placebo, 0.03 and
aripiprazole, 0.22; placebo, 0.02). Changes in the Assessments of Involuntary
Movement Scales were similar for the adjunctive aripiprazole and adjunctive
placebo groups.
Autistic Disorder
In the short-term, placebo-controlled trials in autistic disorder in
pediatric patients (6 to 17 years), the incidence of reported EPS-related
events, excluding events related to akathisia, for aripiprazole-treated patients
was 18% vs. 2% for placebo and the incidence of akathisia-related events for
aripiprazole-treated patients was 3% vs. 9% for placebo.
In the pediatric (6 to 17 years) short-term autistic disorder trials, the
Simpson Angus Rating Scale showed a significant difference between aripiprazole
and placebo (aripiprazole, 0.1; placebo, -0.4). Changes in the Barnes Akathisia
Scale and the Assessments of Involuntary Movement Scales were similar for the
aripiprazole and placebo groups.
Agitation Associated with Schizophrenia
or Bipolar Mania
In the placebo-controlled trials in patients with agitation associated with
schizophrenia or bipolar mania, the incidence of reported EPS-related events
excluding events related to akathisia for aripiprazole-treated patients was 2%
vs. 2% for placebo and the incidence of akathisia-related events for
aripiprazole-treated patients was 2% vs. 0% for placebo. Objectively collected
data on the Simpson Angus Rating Scale (for EPS) and the Barnes Akathisia Scale
(for akathisia) for all treatment groups did not show a difference between
aripiprazole and placebo.
Dystonia
Class Effect: Symptoms of dystonia, prolonged
abnormal contractions of muscle groups, may occur in susceptible individuals
during the first few days of treatment. Dystonic symptoms include: spasm of the
neck muscles, sometimes progressing to tightness of the throat, swallowing
difficulty, difficulty breathing, and/or protrusion of the tongue. While these
symptoms can occur at low doses, they occur more frequently and with greater
severity with high potency and at higher doses of first generation antipsychotic
drugs. An elevated risk of acute dystonia is observed in males and younger age
groups.
Laboratory Test Abnormalities
A between group comparison for 3-week to 6-week, placebo-controlled trials in
adults or 4-week to 8-week, placebo-controlled trials in pediatric patients (6
to 17 years) revealed no medically important differences between the
aripiprazole and placebo groups in the proportions of patients experiencing
potentially clinically significant changes in routine serum chemistry,
hematology, or urinalysis parameters. Similarly, there were no
aripiprazole/placebo differences in the incidence of discontinuations for
changes in serum chemistry, hematology, or urinalysis in adult or pediatric
patients.
In the 6-week trials of aripiprazole as adjunctive therapy for major
depressive disorder, there were no clinically important differences between the
adjunctive aripiprazole-treated and adjunctive placebo-treated patients in the
median change from baseline in prolactin, fasting glucose, HDL, LDL, or total
cholesterol measurements. The median % change from baseline in triglycerides was
5% for adjunctive aripiprazole-treated patients vs. 0% for adjunctive
placebo-treated patients.
In a long-term (26-week), placebo-controlled trial there were no medically
important differences between the aripiprazole and placebo patients in the mean
change from baseline in prolactin, fasting glucose, triglyceride, HDL, LDL, or
total cholesterol measurements.
Weight Gain
In 4-week to 6- week trials in adults with schizophrenia, there was a slight
difference in mean weight gain between aripiprazole and placebo patients (+0.7
kg vs. â’0.05 kg, respectively) and also a difference in the proportion of
patients meeting a weight gain criterion of less then 7% of body weight [aripiprazole
(8%) compared to placebo (3%)]. In a 6-week trial in pediatric patients (13 to
17 years) with schizophrenia, there was a slight difference in mean weight gain
between aripiprazole and placebo patients (+0.13 kg vs. â’0.83 kg, respectively)
and also a difference in the proportion of patients meeting a weight gain
criterion of less then 7% of body weight [aripiprazole (5%) compared to placebo
(1%)].
In 3-week trials in adults with mania with monotherapy aripiprazole, the mean
weight gain for aripiprazole and placebo patients was 0.1 kg vs. 0.0 kg,
respectively. The proportion of patients meeting a weight gain criterion of less then 7%
of body weight was aripiprazole (2%) compared to placebo (3%). In the 6-week
trial in mania with aripiprazole as adjunctive therapy with either lithium or
valproate, the mean weight gain for aripiprazole and placebo patients was 0.6 kg
vs. 0.2 kg, respectively. The proportion of patients meeting a weight gain
criterion of less then 7% of body weight with adjunctive aripiprazole was 3% compared to
adjunctive placebo 4%.
In the trials adding aripiprazole to antidepressants, patients first received
8 weeks of antidepressant treatment followed by 6 weeks of adjunctive
aripiprazole or placebo in addition to their ongoing antidepressant treatment.
The mean weight gain with adjunctive aripiprazole was 1.7 kg vs. 0.4 kg with
adjunctive placebo. The proportion of patients meeting a weight gain criterion
of less then 7% of body weight was 5% with adjunctive aripiprazole compared to 1% with
adjunctive placebo.
In the two short term, placebo-controlled trials in patients (6 to 17 years)
with autistic disorder, the mean increase in body weight in the aripiprazole
group was 1.6 kg vs. 0.4 kg in the placebo group. The proportion of patients
meeting a weight gain criterion of less then 7% of body weight was 26% in aripiprazole
group compared to 7% in placebo group.
Table 13 provides the weight change results from a long-term (26-week),
placebo-controlled study of aripiprazole in adults with schizophrenia, both mean
change from baseline and proportions of patients meeting a weight gain criterion
of less then 7% of body weight relative to baseline, categorized by BMI at baseline.
Although there was no mean weight increase, the aripiprazole group tended to
show more patients with a less then 7% weight gain.
Table 13: Weight Change Results Categorized by BMI at Baseline:
Placebo-Controlled Study in Schizophrenia, Safety Sample
|
BMI greater then 23 |
BMI 23-27 |
BMI less then 27 |
|
Placebo(n=54) |
Aripiprazole(n=59) |
Placebo(n=48) |
Aripiprazole(n=39) |
Placebo(n=49) |
Aripiprazole(n=53) |
Mean change frombaseline (kg) |
-0.5 |
-0.5 |
-0.6 |
-1.3 |
-1.5 |
-2.1 |
% with less then 7% increase BW |
3.7% |
6.8% |
4.2% |
5.1% |
4.1% |
5.7% |
Table 14 provides the weight change results from a long-term (52-week) study
of aripiprazole in adults with schizophrenia, both mean change from baseline and
proportions of patients meeting a weight gain criterion of less then 7% of body weight
relative to baseline, categorized by BMI at baseline:
Table 14: Weight Change Results Categorized by BMI at Baseline:
Active-Controlled Study in Schizophrenia, Safety Sample
|
BMI greater then 23(n=314) |
BMI 23-27(n=265) |
BMI less then 27(n=260) |
Mean change from baseline (kg) |
2.6 |
1.4 |
-1.2 |
% with less then 7% increase BW |
30% |
19% |
8% |
ECG Changes
Between group comparisons for a pooled analysis of placebo-controlled trials
in patients with schizophrenia, bipolar mania, or major depressive disorder
revealed no significant differences between oral aripiprazole and placebo in the
proportion of patients experiencing potentially important changes in ECG
parameters. Aripiprazole was associated with a median increase in heart rate of
2 beats per minute compared to no increase among placebo patients.
In the pooled, placebo-controlled trials in patients with agitation
associated with schizophrenia or bipolar mania, there were no significant
differences between aripiprazole injection and placebo in the proportion of
patients experiencing potentially important changes in ECG parameters, as
measured by standard 12-lead ECGs.
Additional Findings Observed in Clinical
Trials
Adverse Reactions in Long-Term,
Double-Blind, Placebo-Controlled Trials
The adverse reactions reported in a 26-week, double-blind trial comparing
oral ABILIFY and placebo in patients with schizophrenia were generally
consistent with those reported in the short-term, placebo-controlled trials,
except for a higher incidence of tremor [8% (12/153) for ABILIFY vs. 2% (3/153)
for placebo]. In this study, the majority of the cases of tremor were of mild
intensity (8/12 mild and 4/12 moderate), occurred early in therapy (9/12 greater then 49
days), and were of limited duration (7/12 greater then 10 days). Tremor infrequently led to
discontinuation (greater then 1%) of ABILIFY. In addition, in a long-term (52-week),
active-controlled study, the incidence of tremor was 5% (40/859) for ABILIFY. A
similar profile was observed in a long-term study in bipolar disorder.
Other Adverse Reactions Observed During the
Premarketing Evaluation of Aripiprazole
Following is a ul of MedDRA terms that reflect adverse reactions as defined
in ADVERSE REACTIONS(6.1)
reported by patients treated with oral aripiprazole at multiple doses less then 2 mg/day
during any phase of a trial within the database of 13,543 adult patients. All
events assessed as possible adverse drug reactions have been included with the
exception of more commonly occurring events. In addition, medically/clinically
meaningful adverse reactions, particularly those that are likely to be useful to
the prescriber or that have pharmacologic plausibility, have been included.
Events already uled in other parts of ADVERSE REACTIONS(6), or those considered in WARNINGS AND PRECAUTIONS (5)
or
OVERDOSAGE (10)
have been
excluded. Although the reactions reported occurred during treatment with
aripiprazole, they were not necessarily caused by it.
Events are further categorized by MedDRA system organ class and uled in
order of decreasing frequency according to the following definitions: those
occurring in at least 1/100 patients (only those not already uled in the
tabulated results from placebo-controlled trials appear in this uling); those
occurring in 1/100 to 1/1000 patients; and those occurring in fewer than 1/1000
patients.
Adults - Oral Administration
Blood and Lymphatic System Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
leukopenia, neutropenia, thrombocytopenia
Cardiac Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
bradycardia, palpitations, cardiopulmonary failure, myocardial infarction,
cardio-respiratory arrest, atrioventricular block, extrasystoles, sinus
tachycardia, atrial fibrillation, angina pectoris, myocardial ischemia;
greater then 1/1000 patients - atrial flutter, supraventricular
tachycardia, ventricular tachycardia
Eye Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
photophobia, diplopia, eyelid edema, photopsia
Gastrointestinal Disorders:
less then 1/1000 patients and greater then 1/100 patients -
gastroesophageal reflux disease, swollen tongue, esophagitis;
greater then 1/1000 patients - pancreatitis
General Disorders and Administration Site
Conditions:
 less then 1/100 patients - asthenia, peripheral edema,
chest pain; less then 1/1000 patients and greater then 1/100 patients -
face edema, angioedema; greater then 1/1000 patients -
hypothermia
Hepatobiliary Disorders:
greater then 1/1000 patients - hepatitis,
jaundice
Immune System Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
hypersensitivity
Injury, Poisoning, and Procedural Complications:
less then 1/100 patients - fall; less then 1/1000 patients and greater then 1/100 patients - self mutilation; greater then 1/1000 patients - heat stroke
Investigations:
 less then 1/100 patients - weight decreased, creatine
phosphokinase increased; less then 1/1000 patients and greater then 1/100
patients - hepatic enzyme increased, blood glucose increased, blood
prolactin increased, blood urea increased, electrocardiogram QT prolonged, blood
creatinine increased, blood bilirubin increased; greater then 1/1000
patients - blood lactate dehydrogenase increased, glycosylated hemoglobin
increased, gamma-glutamyl transferase increased
Metabolism and Nutrition Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
hyperlipidemia, anorexia, diabetes mellitus (including blood insulin increased,
carbohydrate tolerance decreased, diabetes mellitus non-insulin-dependent,
glucose tolerance impaired, glycosuria, glucose urine, glucose urine present),
hyperglycemia, hypokalemia, hyponatremia, hypoglycemia, polydipsia; greater then 1/1000 patients - diabetic ketoacidosis
Musculoskeletal and Connective Tissue Disorders:
 less then 1/1000 patients and greater then 1/100 patients - muscle
rigidity, muscular weakness, muscle tightness, mobility decreased; greater then 1/1000 patients - rhabdomyolysis
Nervous System Disorders:
less then 1/100 patients - coordination abnormal; less then 1/1000 patients and greater then 1/100 patients - speech disorder,
parkinsonism, memory impairment, cogwheel rigidity, cerebrovascular accident,
hypokinesia, tardive dyskinesia, hypotonia, myoclonus, hypertonia, akinesia,
bradykinesia; greater then 1/1000 patients - Grand Mal
convulsion, choreoathetosis
Psychiatric Disorders:
 less then 1/100 patients - suicidal ideation; less then 1/1000 patients and greater then 1/100 patients - aggression, loss
of libido, suicide attempt, hostility, libido increased, anger, anorgasmia,
delirium, intentional self injury, completed suicide, tic, homicidal ideation; greater then 1/1000 patients - catatonia, sleep
walking
Renal and Urinary Disorders:
 less then 1/1000 patients and greater then 1/100 patients - urinary
retention, polyuria, nocturia
Reproductive System and Breast Disorders:
 less then 1/1000 patients and greater then 1/100 patients -
menstruation irregular, erectile dysfunction, amenorrhea, breast pain; greater then 1/1000 patients - gynaecomastia, priapism
Respiratory, Thoracic, and Mediastinal Disorders:
 less then 1/100 patients - nasal congestion, dyspnea,
pneumonia aspiration
Skin and Subcutaneous Tissue Disorders:
 less then 1/100 patients - rash (including erythematous,
exfoliative, generalized, macular, maculopapular, papular rash; acneiform,
allergic, contact, exfoliative, seborrheic dermatitis, neurodermatitis, and drug
eruption), hyperhydrosis; less then 1/1000 patients and greater then 1/100
patients - pruritus, photosensitivity reaction, alopecia,
urticaria
Vascular Disorders:
 less then 1/100 patients
- hypertension; less then 1/1000 patients and greater then 1/100 patients
-
hypotension
Pediatric Patients - Oral
Administration
Most adverse events observed in the pooled database of 920 pediatric patients
aged 6 to 17 years were also observed in the adult population. Additional
adverse reactions observed in the pediatric population are uled below.
Gastrointestinal Disorders:
less then 1/1000 patients and greater then 1/100 patients
- tongue
dry, tongue spasm
Investigations:
less then 1/100 patients
- blood insulin
increased
Nervous System Disorders:
 less then 1/1000 patients and greater then 1/100 patients
- sleep
talking
Skin and Subcutaneous Tissue Disorders:
 less then 1/1000 patients and greater then 1/100 patients
-
hirsutism
Adults - Intramuscular Injection
Most adverse reactions observed in the pooled database of 749 adult patients
treated with aripiprazole injection, were also observed in the adult population
treated with oral aripiprazole. Additional adverse reactions observed in the
aripiprazole injection population are uled below.
General Disorders and Administration Site
Conditions:
 less then 1/100 patients - injection site reaction; less then 1/1000 patients and greater then 1/100 patients - venipuncture site
bruise
6.3 Postmarketing Experience
The following adverse reactions have been identified during
postapproval use of ABILIFY. Because these reactions are reported voluntarily
from a population of uncertain size, it is not always possible to establish a
causal relationship to drug exposure: rare occurrences of allergic reaction
(anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, or
oropharyngeal spasm), and blood glucose fluctuation.
Commonly observed adverse reactions (incidence ≥5% and at least
twice that for placebo) were (6.2):
- Adult patients with schizophrenia: akathisia
- Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal
disorder, somnolence, and tremor
- Adult patients (monotherapy) with bipolar mania: akathisia, sedation,
restlessness, tremor, and extrapyramidal disorder
- Adult patients (adjunctive therapy with lithium or valproate) with bipolar
mania: akathisia, insomnia, and extrapyramidal disorder
- Pediatric patients (10 to 17 years) with bipolar mania: somnolence,
extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary
hypersecretion, and dizziness
- Adult patients with major depressive disorder (adjunctive treatment to
antidepressant therapy): akathisia, restlessness, insomnia, constipation,
fatigue, and blurred vision
- Pediatric patients (6 to 17 years) with autistic disorder: sedation,
fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite,
salivary hypersecretion, extrapyramidal disorder, and lethargy
- Adult patients with agitation associated with schizophrenia or bipolar
mania: nausea.
To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers
Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Drug Interactions
Given the primary CNS effects of aripiprazole, caution should be
used when ABILIFY is taken in combination with other centrally-acting drugs or
alcohol.
Due to its alpha adrenergic antagonism, aripiprazole has the potential to
enhance the effect of certain antihypertensive agents.
7.1 Potential for Other Drugs to Affect ABILIFY
Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6,
CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not
undergo direct glucuronidation. This suggests that an interaction of
aripiprazole with inhibitors or inducers of these enzymes, or other factors,
like smoking, is unlikely.
Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents
that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole
clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or
CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole
elimination and cause increased blood levels.
Ketoconazole and Other CYP3A4 Inhibitors
Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single
dose of aripiprazole increased the AUC of aripiprazole and its active metabolite
by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400
mg/day) has not been studied. When ketoconazole is given concomitantly with
aripiprazole, the aripiprazole dose should be reduced to one-half of its normal
dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have
similar effects and need similar dose reductions; moderate inhibitors
(erythromycin, grapefruit juice) have not been studied. When the CYP3A4
inhibitor is withdrawn from the combination therapy, the aripiprazole dose
should be increased.
Quinidine and Other CYP2D6 Inhibitors
Coadministration of a 10 mg single dose of aripiprazole with quinidine (166
mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of
aripiprazole by 112% but decreased the AUC of its active metabolite,
dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of
its normal dose when quinidine is given concomitantly with aripiprazole. Other
significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be
expected to have similar effects and should lead to similar dose reductions.
When the CYP2D6 inhibitor is withdrawn from the combination therapy, the
aripiprazole dose should be increased. When adjunctive ABILIFY is administered
to patients with major depressive disorder, ABILIFY should be administered
without dosage adjustment as specified in DOSAGE AND
ADMINISTRATION (2.3)
.
Carbamazepine and Other CYP3A4 Inducers
Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4
inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease
in Cmax and AUC values of both aripiprazole and its active metabolite,
dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy,
aripiprazole dose should be doubled. Additional dose increases should be based
on clinical evaluation. When carbamazepine is withdrawn from the combination
therapy, the aripiprazole dose should be reduced.
7.2 Potential for ABILIFY to Affect Other Drugs
Aripiprazole is unlikely to cause clinically important
pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
In in vivo studies, 10 mg/day to 30 mg/day doses of
aripiprazole had no significant effect on metabolism by CYP2D6
(dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and
CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and
dehydro-aripiprazole did not show potential for altering CYP1A2-mediated
metabolism in vitro.
No effect of aripiprazole was seen on the pharmacokinetics of lithium or
valproate.
Alcohol
There was no significant difference between aripiprazole coadministered with
ethanol and placebo coadministered with ethanol on performance of gross motor
skills or stimulus response in healthy subjects. As with most psychoactive
medications, patients should be advised to avoid alcohol while taking
ABILIFY.
7.3 Drugs Having No Clinically Important Interactions with
ABILIFY
Famotidine
Coadministration of aripiprazole (given in a single dose of 15 mg) with a 40
mg single dose of the H2 antagonist famotidine, a potent
gastric acid blocker, decreased the solubility of aripiprazole and, hence, its
rate of absorption, reducing by 37% and 21% the Cmax of aripiprazole and
dehydro-aripiprazole, respectively, and by 13% and 15%, respectively, the extent
of absorption (AUC). No dosage adjustment of aripiprazole is required when
administered concomitantly with famotidine.
Valproate
When valproate (500 mg/day-1500 mg/day) and aripiprazole (30 mg/day) were
coadministered, at steady-state the Cmax and AUC of aripiprazole were decreased
by 25%. No dosage adjustment of aripiprazole is required when administered
concomitantly with valproate.
When aripiprazole (30 mg/day) and valproate (1000 mg/day) were
coadministered, at steady-state there were no clinically significant changes in
the Cmax or AUC of valproate. No dosage adjustment of valproate is required when
administered concomitantly with aripiprazole.
Lithium
A pharmacokinetic interaction of aripiprazole with lithium is unlikely
because lithium is not bound to plasma proteins, is not metabolized, and is
almost entirely excreted unchanged in urine. Coadministration of therapeutic
doses of lithium (1200 mg/day-1800 mg/day) for 21 days with aripiprazole (30
mg/day) did not result in clinically significant changes in the pharmacokinetics
of aripiprazole or its active metabolite, dehydro-aripiprazole (Cmax and AUC
increased by less than 20%). No dosage adjustment of aripiprazole is required
when administered concomitantly with lithium.
Coadministration of aripiprazole (30 mg/day) with lithium (900 mg/day) did
not result in clinically significant changes in the pharmacokinetics of lithium.
No dosage adjustment of lithium is required when administered concomitantly with
aripiprazole.
Lamotrigine
Coadministration of 10 mg/day to 30 mg/day oral doses of aripiprazole for 14
days to patients with bipolar I disorder had no effect on the steady-state
pharmacokinetics of 100 mg/day to 400 mg/day lamotrigine, a
UDP-glucuronosyltransferase 1A4 substrate. No dosage adjustment of lamotrigine
is required when aripiprazole is added to lamotrigine.
Dextromethorphan
Aripiprazole at doses of 10 mg/day to 30 mg/day for 14 days had no effect on
dextromethorphan’s O-dealkylation to its major metabolite, dextrorphan, a
pathway dependent on CYP2D6 activity. Aripiprazole also had no effect on
dextromethorphan’s N-demethylation to its metabolite 3-methoxymorphinan, a
pathway dependent on CYP3A4 activity. No dosage adjustment of dextromethorphan
is required when administered concomitantly with aripiprazole.
Warfarin
Aripiprazole 10 mg/day for 14 days had no effect on the pharmacokinetics of
R-warfarin and S-warfarin or on the pharmacodynamic end point of International
Normalized Ratio, indicating the lack of a clinically relevant effect of
aripiprazole on CYP2C9 and CYP2C19 metabolism or the binding of highly
protein-bound warfarin. No dosage adjustment of warfarin is required when
administered concomitantly with aripiprazole.
Omeprazole
Aripiprazole 10 mg/day for 15 days had no effect on the pharmacokinetics of a
single 20 mg dose of omeprazole, a CYP2C19 substrate, in healthy subjects. No
dosage adjustment of omeprazole is required when administered concomitantly with
aripiprazole.
Lorazepam
Coadministration of lorazepam injection (2 mg) and aripiprazole injection (15
mg) to healthy subjects (n=40: 35 males and 5 females; ages 19-45 years old) did
not result in clinically important changes in the pharmacokinetics of either
drug. No dosage adjustment of aripiprazole is required when administered
concomitantly with lorazepam. However, the intensity of sedation was greater
with the combination as compared to that observed with aripiprazole alone and
the orthostatic hypotension observed was greater with the combination as
compared to that observed with lorazepam alone [see WARNINGS
AND PRECAUTIONS (5.6)].
Escitalopram
Coadministration of 10 mg/day oral doses of aripiprazole for 14 days to
healthy subjects had no effect on the steady-state pharmacokinetics of 10 mg/day
escitalopram, a substrate of CYP2C19 and CYP3A4. No dosage adjustment of
escitalopram is required when aripiprazole is added to escitalopram.
Venlafaxine
Coadministration of 10 mg/day to 20 mg/day oral doses of aripiprazole for 14
days to healthy subjects had no effect on the steady-state pharmacokinetics of
venlafaxine and O-desmethylvenlafaxine following 75 mg/day venlafaxine XR, a
CYP2D6 substrate. No dosage adjustment of venlafaxine is required when
aripiprazole is added to venlafaxine.
Fluoxetine, Paroxetine, and Sertraline
A population pharmacokinetic analysis in patients with major depressive
disorder showed no substantial change in plasma concentrations of fluoxetine (20
mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline
(100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma
concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%,
respectively, and concentrations of paroxetine decreased by about 27%. The
steady-state plasma concentrations of sertraline and desmethylsertraline were
not substantially changed when these antidepressant therapies were
coadministered with aripiprazole. Aripiprazole dosing was 2 mg/day to 15 mg/day
(when given with fluoxetine or paroxetine) or 2 mg/day to 20 mg/day (when given
with sertraline).
-
Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg,
fluoxetine) inhibitors will increase ABILIFY drug concentrations; reduce
ABILIFY dose by one-half when used concomitantly (2.6, 7.1), except when used
as adjunctive treatment with antidepressants (2.6)
-
CYP3A4 inducers (eg, carbamazepine) will decrease
ABILIFY drug concentrations; double ABILIFY dose when used concomitantly (2.6, 7.1)
|
See 17 for
PATIENT COUNSELING INFORMATION and the FDA-approved Medication Guide |
Use In Specific Populations
In general, no dosage adjustment for ABILIFY is required on the
basis of a patient’s age, gender, race, smoking status, hepatic function, or
renal function [see DOSAGE AND ADMINISTRATION (2.5)].
8.1 Pregnancy
Pregnancy Category C: In animal
studies, aripiprazole demonstrated developmental toxicity, including possible
teratogenic effects in rats and rabbits.
Pregnant rats were treated with oral doses of 3 mg/kg/day, 10 mg/kg/day, and
30 mg/kg/day (1 times, 3 times, and 10 times the maximum recommended human dose
[MRHD] on a mg/m2 basis) of aripiprazole during the
period of organogenesis. Gestation was slightly prolonged at 30 mg/kg. Treatment
caused a slight delay in fetal development, as evidenced by decreased fetal
weight (30 mg/kg), undescended testes (30 mg/kg), and delayed skeletal
ossification (10 mg/kg and 30 mg/kg). There were no adverse effects on
embryofetal or pup survival. Delivered offspring had decreased body weights (10
mg/kg and 30 mg/kg), and increased incidences of hepatodiaphragmatic nodules and
diaphragmatic hernia at 30 mg/kg (the other dose groups were not examined for
these findings). A low incidence of diaphragmatic hernia was also seen in the
fetuses exposed to 30 mg/kg. Postnatally, delayed vaginal opening was seen at 10
mg/kg and 30 mg/kg and impaired reproductive performance (decreased fertility
rate, corpora lutea, implants, live fetuses, and increased post-implantation
loss, likely mediated through effects on female offspring) was seen at 30 mg/kg.
Some maternal toxicity was seen at 30 mg/kg; however, there was no evidence to
suggest that these developmental effects were secondary to maternal
toxicity.
In pregnant rats receiving aripiprazole injection intravenously (3 mg/kg/day,
9 mg/kg/day, and 27 mg/kg/day) during the period of organogenesis, decreased
fetal weight and delayed skeletal ossification were seen at the highest dose,
which also caused some maternal toxicity.
Pregnant rabbits were treated with oral doses of 10 mg/kg/day, 30 mg/kg/day,
and 100 mg/kg/day (2 times, 3 times, and 11 times human exposure at MRHD based
on AUC and 6 times, 19 times, and 65 times the MRHD based on mg/m2) of aripiprazole during the period of organogenesis.
Decreased maternal food consumption and increased abortions were seen at 100
mg/kg. Treatment caused increased fetal mortality (100 mg/kg), decreased fetal
weight (30 mg/kg and 100 mg/kg), increased incidence of a skeletal abnormality
(fused sternebrae at 30 mg/kg and 100 mg/kg), and minor skeletal variations (100
mg/kg).
In pregnant rabbits receiving aripiprazole injection intravenously (3
mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day) during the period of organogenesis,
the highest dose, which caused pronounced maternal toxicity, resulted in
decreased fetal weight, increased fetal abnormalities (primarily skeletal), and
decreased fetal skeletal ossification. The fetal no-effect dose was 10 mg/kg,
which produced 5 times the human exposure at the MRHD based on AUC and is 6
times the MRHD based on mg/m2.
In a study in which rats were treated with oral doses of 3 mg/kg/day, 10
mg/kg/day, and 30 mg/kg/day (1 times, 3 times, and 10 times the MRHD on a
mg/m2 basis) of aripiprazole perinatally and postnatally
(from day 17 of gestation through day 21 postpartum), slight maternal toxicity
and slightly prolonged gestation were seen at 30 mg/kg. An increase in
stillbirths and decreases in pup weight (persisting into adulthood) and survival
were seen at this dose.
In rats receiving aripiprazole injection intravenously (3 mg/kg/day, 8
mg/kg/day, and 20 mg/kg/day) from day 6 of gestation through day 20 postpartum,
an increase in stillbirths was seen at 8 mg/kg and 20 mg/kg, and decreases in
early postnatal pup weights and survival were seen at 20 mg/kg. These doses
produced some maternal toxicity. There were no effects on postnatal behavioral
and reproductive development.
There are no adequate and well-controlled studies in pregnant women. It is
not known whether aripiprazole can cause fetal harm when administered to a
pregnant woman or can affect reproductive capacity. Aripiprazole should be used
during pregnancy only if the potential benefit outweighs the potential risk to
the fetus.
8.2 Labor and Delivery
The effect of aripiprazole on labor and delivery in humans is
unknown.
8.3 Nursing Mothers
Aripiprazole was excreted in milk of rats during lactation. It is
not known whether aripiprazole or its metabolites are excreted in human milk. It
is recommended that women receiving aripiprazole should not breast-feed.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients with major
depressive disorder or agitation associated with schizophrenia or bipolar mania
have not been established.
Safety and effectiveness in pediatric patients with schizophrenia were
established in a 6-week, placebo-controlled clinical trial in 202 pediatric
patients aged 13 to 17 years [see INDICATIONS AND USAGE (1.1),
DOSAGE AND
ADMINISTRATION (2.1),
ADVERSE REACTIONS (6.2), and
CLINICAL STUDIES (14.1)].
Although maintenance efficacy in pediatric patients has not been systematically
evaluated, maintenance efficacy can be extrapolated from adult data along with
comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric
patients.
Safety and effectiveness in pediatric patients with bipolar mania were
established in a 4-week, placebo-controlled clinical trial in 197 pediatric
patients aged 10 to 17 years [see INDICATIONS AND USAGE (1.2),
DOSAGE AND
ADMINISTRATION (2.2),
ADVERSE REACTIONS (6.2), and
CLINICAL STUDIES (14.2)].
Although maintenance efficacy in pediatric patients has not been systematically
evaluated, maintenance efficacy can be extrapolated from adult data along with
comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric
patients.
The efficacy of adjunctive ABILIFY with concomitant lithium or valproate in
the treatment of manic or mixed episodes in pediatric patients has not been
systematically evaluated. However, such efficacy and lack of pharmacokinetic
interaction between aripiprazole and lithium or valproate can be extrapolated
from adult data, along with comparisons of aripiprazole pharmacokinetic
parameters in adult and pediatric patients.
Safety and effectiveness in pediatric patients demonstrating irritability
associated with autistic disorder were established in two 8 week,
placebo-controlled clinical trials in 212 pediatric patients aged 6 to 17 years
[see INDICATIONS AND USAGE (1.4)
, DOSAGE AND
ADMINISTRATION (2.4)
, ADVERSE REACTIONS (6.2), and
CLINICAL STUDIES (14.4)]. Maintenance efficacy in pediatric
patients has not been systematically evaluated.
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric
patients 10 to 17 years of age were similar to those in adults after correcting
for the differences in body weights.
8.5 Geriatric Use
In formal single-dose pharmacokinetic studies (with aripiprazole
given in a single dose of 15 mg), aripiprazole clearance was 20% lower in
elderly (less then 65 years) subjects compared to younger adult subjects (18 to 64
years). There was no detectable age effect, however, in the population
pharmacokinetic analysis in schizophrenia patients. Also, the pharmacokinetics
of aripiprazole after multiple doses in elderly patients appeared similar to
that observed in young, healthy subjects. No dosage adjustment is recommended
for elderly patients [see also BOXED
WARNING and
WARNINGS AND PRECAUTIONS (5.1)].
Of the 13,543 patients treated with oral aripiprazole in clinical trials,
1073 (8%) were less then 65 years old and 799 (6%) were less then 75 years old. The majority (81%)
of the 1073 patients were diagnosed with Dementia of the Alzheimer’s type.
Placebo-controlled studies of oral aripiprazole in schizophrenia, bipolar
mania, or major depressive disorder did not include sufficient numbers of
subjects aged 65 and over to determine whether they respond differently from
younger subjects.
Of the 749 patients treated with aripiprazole injection in clinical trials,
99 (13%) were less then 65 years old and 78 (10%) were less then 75 years old. Placebo-controlled
studies of aripiprazole injection in patients with agitation associated with
schizophrenia or bipolar mania did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger
subjects.
Studies of elderly patients with psychosis associated with Alzheimer’s
disease have suggested that there may be a different tolerability profile in
this population compared to younger patients with schizophrenia [see also BOXED WARNING and
WARNINGS AND PRECAUTIONS (5.1)].
The safety and efficacy of ABILIFY in the treatment of patients with psychosis
associated with Alzheimer’s disease has not been established. If the prescriber
elects to treat such patients with ABILIFY, vigilance should be exercised.
8.6 Renal Impairment
In patients with severe renal impairment (creatinine clearance greater then 30 mL/min), Cmax of aripiprazole (given in a single dose of 15 mg) and
dehydro-aripiprazole increased by 36% and 53%, respectively, but AUC was 15%
lower for aripiprazole and 7% higher for dehydro-aripiprazole. Renal excretion
of both unchanged aripiprazole and dehydro-aripiprazole is less than 1% of the
dose. No dosage adjustment is required in subjects with renal impairment.
8.7 Hepatic Impairment
In a single-dose study (15 mg of aripiprazole) in subjects with
varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C), the AUC of
aripiprazole, compared to healthy subjects, increased 31% in mild HI, increased
8% in moderate HI, and decreased 20% in severe HI. None of these differences
would require dose adjustment.
8.8 Gender
Cmax and AUC of aripiprazole and its active metabolite,
dehydro-aripiprazole, are 30% to 40% higher in women than in men, and
correspondingly, the apparent oral clearance of aripiprazole is lower in women.
These differences, however, are largely explained by differences in body weight
(25%) between men and women. No dosage adjustment is recommended based on
gender.
8.9 Race
Although no specific pharmacokinetic study was conducted to
investigate the effects of race on the disposition of aripiprazole, population
pharmacokinetic evaluation revealed no evidence of clinically significant
race-related differences in the pharmacokinetics of aripiprazole. No dosage
adjustment is recommended based on race.
8.10 Smoking
Based on studies utilizing human liver enzymes in vitro, aripiprazole is not a substrate for CYP1A2 and
also does not undergo direct glucuronidation. Smoking should, therefore, not
have an effect on the pharmacokinetics of aripiprazole. Consistent with these
in vitro results, population pharmacokinetic
evaluation did not reveal any significant pharmacokinetic differences between
smokers and nonsmokers. No dosage adjustment is recommended based on smoking
status.
Drug Abuse And Dependence
9.1 Controlled Substance
ABILIFY (aripiprazole) is not a controlled substance.
9.2 Abuse and Dependence
Aripiprazole has not been systematically studied in humans for
its potential for abuse, tolerance, or physical dependence. In physical
dependence studies in monkeys, withdrawal symptoms were observed upon abrupt
cessation of dosing. While the clinical trials did not reveal any tendency for
any drug-seeking behavior, these observations were not systematic and it is not
possible to predict on the basis of this limited experience the extent to which
a CNS-active drug will be misused, diverted, and/or abused once marketed.
Consequently, patients should be evaluated carefully for a history of drug
abuse, and such patients should be observed closely for signs of ABILIFY misuse
or abuse (eg, development of tolerance, increases in dose, drug-seeking
behavior).
Overdosage
MedDRA terminology has been used to classify the adverse
reactions.
10.1 Human Experience
A total of 76 cases of deliberate or accidental overdosage with
oral aripiprazole have been reported worldwide. These include overdoses with
oral aripiprazole alone and in combination with other substances. No fatality
was reported from these cases. Of the 44 cases with known outcome, 33 cases
recovered without sequelae and one case recovered with sequelae (mydriasis and
feeling abnormal). The largest known case of acute ingestion with a known
outcome involved 1080 mg of oral aripiprazole (36 times the maximum recommended
daily dose) in a patient who fully recovered. Included in the 76 cases are 10
cases of deliberate or accidental overdosage in children (age 12 and younger)
involving oral aripiprazole ingestions up to 195 mg with no fatalities.
Common adverse reactions (reported in at least 5% of all overdose cases)
reported with oral aripiprazole overdosage (alone or in combination with other
substances) include vomiting, somnolence, and tremor. Other clinically important
signs and symptoms observed in one or more patients with aripiprazole overdoses
(alone or with other substances) include acidosis, aggression, aspartate
aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional
state, convulsion, blood creatine phosphokinase increased, depressed level of
consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of
consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration,
respiratory arrest, status epilepticus, and tachycardia.
10.2 Management of Overdosage
No specific information is available on the treatment of overdose
with aripiprazole. An electrocardiogram should be obtained in case of overdosage
and if QT interval prolongation is present, cardiac monitoring should be
instituted. Otherwise, management of overdose should concentrate on supportive
therapy, maintaining an adequate airway, oxygenation and ventilation, and
management of symptoms. Close medical supervision and monitoring should continue
until the patient recovers.
Charcoal: In the event of an overdose of ABILIFY,
an early charcoal administration may be useful in partially preventing the
absorption of aripiprazole. Administration of 50 g of activated charcoal, one
hour after a single 15 mg oral dose of aripiprazole, decreased the mean AUC and
Cmax of aripiprazole by 50%.
Hemodialysis: Although there is no information on
the effect of hemodialysis in treating an overdose with aripiprazole,
hemodialysis is unlikely to be useful in overdose management since aripiprazole
is highly bound to plasma proteins.
Description
Aripiprazole is a psychotropic drug that is available as ABILIFY(aripiprazole) Tablets, ABILIFY DISCMELT(aripiprazole) Orally Disintegrating Tablets, ABILIFY(aripiprazole) Oral Solution, and ABILIFY(aripiprazole) Injection, a solution for intramuscular injection. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C23H27Cl2N3O2 and its molecular weight is 448.38. The chemical structure is:
ABILIFY Tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.ABILIFY DISCMELT Orally Disintegrating Tablets are available in 10 mg and 15 mg strengths. Inactive ingredients include acesulfame potassium, aspartame, calcium silicate, croscarmellose sodium, crospovidone, crde vanilla (natural and artificial flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and xylitol. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.ABILIFY Oral Solution is a clear, colorless to light yellow solution available in a concentration of 1 mg/mL. The inactive ingredients for this solution include disodium edetate, fructose, glycerin, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose, and purified water. The oral solution is flavored with natural orange cream and other natural flavors.ABILIFY Injection is available in single-dose vials as a ready-to-use, 9.75 mg/1.3 mL (7.5 mg/mL) clear, colorless, sterile, aqueous solution for intramuscular use only. Inactive ingredients for this solution include 150 mg/mL of sulfobutylether(SBECD), tartaric acid, sodium hydroxide, and water for injection.
Clinical Pharmacology
12.1 Mechanism of Action
The mechanism of action of aripiprazole, as with other drugs
having efficacy in schizophrenia, bipolar disorder, major depressive disorder,
irritability associated with autistic disorder, and agitation associated with
schizophrenia or bipolar disorder, is unknown. However, it has been proposed
that the efficacy of aripiprazole is mediated through a combination of partial
agonist activity at D2 and 5-HT1A
receptors and antagonist activity at 5-HT2A receptors.
Actions at receptors other than D2, 5-HT1A, and 5-HT2A may explain some of the
other clinical effects of aripiprazole (eg, the orthostatic hypotension observed
with aripiprazole may be explained by its antagonist activity at adrenergic
alpha1 receptors).
12.2 Pharmacodynamics
Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively),
moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors
(Ki values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM,
respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for
cholinergic muscarinic receptors (IC50>1000 nM).
Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors,
and as an antagonist at serotonin 5-HT2A receptor.
12.3 Pharmacokinetics
ABILIFY activity is presumably primarily due to the parent drug,
aripiprazole, and to a lesser extent, to its major metabolite,
dehydro-aripiprazole, which has been shown to have affinities for D2 receptors similar to the parent drug and represents 40% of
the parent drug exposure in plasma. The mean elimination half-lives are about 75
hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively.
Steady-state concentrations are attained within 14 days of dosing for both
active moieties. Aripiprazole accumulation is predictable from single-dose
pharmacokinetics. At steady-state, the pharmacokinetics of aripiprazole are
dose-proportional. Elimination of aripiprazole is mainly through hepatic
metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
Pharmacokinetic studies showed that ABILIFY DISCMELT Orally Disintegrating
Tablets are bioequivalent to ABILIFY Tablets.
ORAL ADMINISTRATION
Absorption
Tablet: Aripiprazole is well absorbed after
administration of the tablet, with peak plasma concentrations occurring within 3
hours to 5 hours; the absolute oral bioavailability of the tablet formulation is
87%. ABILIFY can be administered with or without food. Administration of a 15 mg
ABILIFY Tablet with a standard high-fat meal did not significantly affect the
Cmax or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but
delayed Tmax by 3 hours for aripiprazole and 12 hours for
dehydro-aripiprazole.
Oral Solution: Aripiprazole is well absorbed when
administered orally as the solution. At equivalent doses, the plasma
concentrations of aripiprazole from the solution were higher than that from the
tablet formulation. In a relative bioavailability study comparing the
pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg
aripiprazole tablets in healthy subjects, the solution to tablet ratios of
geometric mean Cmax and AUC values were 122% and 114%, respectively [see DOSAGE AND ADMINISTRATION (2.6)]. The single-dose pharmacokinetics of
aripiprazole were linear and dose-proportional between the doses of 5 mg to 30
mg.
Distribution
The steady-state volume of distribution of aripiprazole following intravenous
administration is high (404 L or 4.9 L/kg), indicating extensive extravascular
distribution. At therapeutic concentrations, aripiprazole and its major
metabolite are greater than 99% bound to serum proteins, primarily to albumin.
In healthy human volunteers administered 0.5 mg/day to 30 mg/day aripiprazole
for 14 days, there was dose-dependent D2 receptor
occupancy indicating brain penetration of aripiprazole in humans.
Metabolism and Elimination
Aripiprazole is metabolized primarily by three biotransformation pathways:
dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible
for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is
catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic
circulation. At steady-state, dehydro-aripiprazole, the active metabolite,
represents about 40% of aripiprazole AUC in plasma.
Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6
substrates and are classified as poor metabolizers (PM), whereas the rest are
extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole
exposure and about a 30% decrease in exposure to the active metabolite compared
to EMs, resulting in about a 60% higher exposure to the total active moieties
from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY
with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs,
approximately doubles aripiprazole plasma exposure, and dose adjustment is
needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about
75 hours and 146 hours for aripiprazole in EMs and PMs, respectively.
Aripiprazole does not inhibit or induce the CYP2D6 pathway.
Following a single oral dose of [14C]-labeled
aripiprazole, approximately 25% and 55% of the administered radioactivity was
recovered in the urine and feces, respectively. Less than 1% of unchanged
aripiprazole was excreted in the urine and approximately 18% of the oral dose
was recovered unchanged in the feces.
INTRAMUSCULAR ADMINISTRATION
In two pharmacokinetic studies of aripiprazole injection administered
intramuscularly to healthy subjects, the median times to the peak plasma
concentrations were at 1 hour and 3 hours. A 5 mg intramuscular injection of
aripiprazole had an absolute bioavailability of 100%. The geometric mean maximum
concentration achieved after an intramuscular dose was on average 19% higher
than the Cmax of the oral tablet. While the systemic exposure over 24 hours was
generally similar between aripiprazole injection given intramuscularly and after
oral tablet administration, the aripiprazole AUC in the first 2 hours after an
intramuscular injection was 90% greater than the AUC after the same dose as a
tablet. In stable patients with schizophrenia or schizoaffective disorder, the
pharmacokinetics of aripiprazole after intramuscular administration were linear
over a dose range of 1 mg to 45 mg. Although the metabolism of aripiprazole
injection was not systematically evaluated, the intramuscular route of
administration would not be expected to alter the metabolic pathways.
Nonclinical Toxicology
13.1 Carcinogenesis, Mutagenesis, Impairment of
Fertility
Carcinogenesis
Lifetime carcinogenicity studies were conducted in ICR mice and in
Sprague-Dawley (SD) and F344 rats. Aripiprazole was administered for 2 years in
the diet at doses of 1 mg/kg/day, 3 mg/kg/day, 10 mg/kg/day, and 30 mg/kg/day to
ICR mice and 1 mg/kg/day, 3 mg/kg/day, and 10 mg/kg/day to F344 rats (0.2 times
to 5 times and 0.3 times to 3 times the maximum recommended human dose [MRHD]
based on mg/m2, respectively). In addition, SD rats were
dosed orally for 2 years at 10 mg/kg/day, 20 mg/kg/day, 40 mg/kg/day, and 60
mg/kg/day (3 times to 19 times the MRHD based on mg/m2).
Aripiprazole did not induce tumors in male mice or rats. In female mice, the
incidences of pituitary gland adenomas and mammary gland adenocarcinomas and
adenoacanthomas were increased at dietary doses of 3 mg/kg/day to 30 mg/kg/day
(0.1 times to 0.9 times human exposure at MRHD based on AUC and 0.5 times to 5
times the MRHD based on mg/m2). In female rats, the
incidence of mammary gland fibroadenomas was increased at a dietary dose of 10
mg/kg/day (0.1 times human exposure at MRHD based on AUC and 3 times the MRHD
based on mg/m2); and the incidences of adrenocortical
carcinomas and combined adrenocortical adenomas/carcinomas were increased at an
oral dose of 60 mg/kg/day (14 times human exposure at MRHD based on AUC and 19
times the MRHD based on mg/m2).
Proliferative changes in the pituitary and mammary gland of rodents have been
observed following chronic administration of other antipsychotic agents and are
considered prolactin-mediated. Serum prolactin was not measured in the
aripiprazole carcinogenicity studies. However, increases in serum prolactin
levels were observed in female mice in a 13-week dietary study at the doses
associated with mammary gland and pituitary tumors. Serum prolactin was not
increased in female rats in 4-week and 13-week dietary studies at the dose
associated with mammary gland tumors. The relevance for human risk of the
findings of prolactin-mediated endocrine tumors in rodents is unknown.
Mutagenesis
The mutagenic potential of aripiprazole was tested in the in vitro bacterial reverse-mutation assay, the in vitro bacterial DNA repair assay, the in vitro forward gene mutation assay in mouse lymphoma
cells, the in vitro chromosomal aberration assay in
Chinese hamster lung (CHL) cells, the in vivo
micronucleus assay in mice, and the unscheduled DNA synthesis assay in rats.
Aripiprazole and a metabolite (2,3-DCPP) were clastogenic in the in vitro chromosomal aberration assay in CHL cells with and
without metabolic activation. The metabolite, 2,3-DCPP, produced increases in
numerical aberrations in the in vitro assay in CHL
cells in the absence of metabolic activation. A positive response was obtained
in the in vivo micronucleus assay in mice; however,
the response was due to a mechanism not considered relevant to humans.
Impairment of Fertility
Female rats were treated with oral doses of 2 mg/kg/day, 6 mg/kg/day, and 20
mg/kg/day (0.6 times, 2 times, and 6 times the maximum recommended human dose
[MRHD] on a mg/m2 basis) of aripiprazole from 2 weeks
prior to mating through day 7 of gestation. Estrus cycle irregularities and
increased corpora lutea were seen at all doses, but no impairment of fertility
was seen. Increased pre-implantation loss was seen at 6 mg/kg and 20 mg/kg and
decreased fetal weight was seen at 20 mg/kg.
Male rats were treated with oral doses of 20 mg/kg/day, 40 mg/kg/day, and 60
mg/kg/day (6 times, 13 times, and 19 times the MRHD on a mg/m2 basis) of aripiprazole from 9 weeks prior to mating through
mating. Disturbances in spermatogenesis were seen at 60 mg/kg and prostate
atrophy was seen at 40 mg/kg and 60 mg/kg, but no impairment of fertility was
seen.
13.2 Animal Toxicology and/or Pharmacology
Aripiprazole produced retinal degeneration in albino rats in a
26-week chronic toxicity study at a dose of 60 mg/kg and in a 2-year
carcinogenicity study at doses of 40 mg/kg and 60 mg/kg. The 40 mg/kg and 60
mg/kg doses are 13 times and 19 times the maximum recommended human dose (MRHD)
based on mg/m2 and 7 times to 14 times human exposure at
MRHD based on AUC. Evaluation of the retinas of albino mice and of monkeys did
not reveal evidence of retinal degeneration. Additional studies to further
evaluate the mechanism have not been performed. The relevance of this finding to
human risk is unknown.
Clinical Studies
14.1 Schizophrenia
Adult
The efficacy of ABILIFY (aripiprazole) in the treatment of schizophrenia was
evaluated in five short-term (4-week and 6-week), placebo-controlled trials of
acutely relapsed inpatients who predominantly met DSM-III/IV criteria for
schizophrenia. Four of the five trials were able to distinguish aripiprazole
from placebo, but one study, the smallest, did not. Three of these studies also
included an active control group consisting of either risperidone (one trial) or
haloperidol (two trials), but they were not designed to allow for a comparison
of ABILIFY and the active comparators.
In the four positive trials for ABILIFY, four primary measures were used for
assessing psychiatric signs and symptoms. The Positive and Negative Syndrome
Scale (PANSS) is a multi-li inventory of general psychopathology used to
evaluate the effects of drug treatment in schizophrenia. The PANSS positive
subscale is a subset of lis in the PANSS that rates seven positive symptoms of
schizophrenia (delusions, conceptual disorganization, hallucinatory behavior,
exclient, grandiosity, suspiciousness/persecution, and hostility). The PANSS
negative subscale is a subset of lis in the PANSS that rates seven negative
symptoms of schizophrenia (blunted affect, emotional withdrawal, poor rapport,
passive apathetic withdrawal, difficulty in abstract thinking, lack of
spontaneity/flow of conversation, stereotyped thinking). The Clinical Global
Impression (CGI) assessment reflects the impression of a skilled observer, fully
familiar with the manifestations of schizophrenia, about the overall clinical
state of the patient.
 In a 4-week trial (n=414) comparing two fixed doses of ABILIFY (15 mg/day or
30 mg/day) to placebo, both doses of ABILIFY were superior to placebo in the
PANSS total score, PANSS positive subscale, and CGI-severity score. In addition,
the 15 mg dose was superior to placebo in the PANSS negative subscale.
 In a 4-week trial (n=404) comparing two fixed doses of ABILIFY (20 mg/day or
30 mg/day) to placebo, both doses of ABILIFY were superior to placebo in the
PANSS total score, PANSS positive subscale, PANSS negative subscale, and
CGI-severity score.
 In a 6-week trial (n=420) comparing three fixed doses of ABILIFY (10 mg/day,
15 mg/day, or 20 mg/day) to placebo, all three doses of ABILIFY were superior to
placebo in the PANSS total score, PANSS positive subscale, and the PANSS
negative subscale.
 In a 6-week trial (n=367) comparing three fixed doses of ABILIFY (2 mg/day,
5 mg/day, or 10 mg/day) to placebo, the 10 mg dose of ABILIFY was superior to
placebo in the PANSS total score, the primary outcome measure of the study. The
2 mg and 5 mg doses did not demonstrate superiority to placebo on the primary
outcome measure.
 In a fifth study, a 4-week trial (n=103) comparing ABILIFY in a range of 5
mg/day to 30 mg/day to placebo, ABILIFY was only significantly different
compared to placebo in a responder analysis based on the CGI-severity score, a
primary outcome for that trial.
Thus, the efficacy of 10 mg, 15 mg, 20 mg, and 30 mg daily doses was
established in two studies for each dose. Among these doses, there was no
evidence that the higher dose groups offered any advantage over the lowest dose
group of these studies.
An examination of population subgroups did not reveal any clear evidence of
differential responsiveness on the basis of age, gender, or race.
A longer-term trial enrolled 310 inpatients or outpatients meeting DSM-IV
criteria for schizophrenia who were, by history, symptomatically stable on other
antipsychotic medications for periods of 3 months or longer. These patients were
discontinued from their antipsychotic medications and randomized to ABILIFY 15
mg/day or placebo for up to 26 weeks of observation for relapse. Relapse during
the double-blind phase was defined as CGI-Improvement score of ≥5 (minimally
worse), scores ≥5 (moderately severe) on the hostility or uncooperativeness
lis of the PANSS, or ≥20% increase in the PANSS total score. Patients
receiving ABILIFY 15 mg/day experienced a significantly longer time to relapse
over the subsequent 26 weeks compared to those receiving placebo.
Pediatric Patients
The efficacy of ABILIFY (aripiprazole) in the treatment of schizophrenia in
pediatric patients (13 to 17 years of age) was evaluated in one 6-week,
placebo-controlled trial of outpatients who met DSM-IV criteria for
schizophrenia and had a PANSS score ≥70 at baseline. In this trial (n=302)
comparing two fixed doses of ABILIFY (10 mg/day or 30 mg/day) to placebo,
ABILIFY was titrated starting from 2 mg/day to the target dose in 5 days in the
10 mg/day treatment arm and in 11 days in the 30 mg/day treatment arm. Both
doses of ABILIFY were superior to placebo in the PANSS total score, the primary
outcome measure of the study. The 30 mg/day dosage was not shown to be more
efficacious than the 10 mg/day dose. Although maintenance efficacy in pediatric
patients has not been systematically evaluated, maintenance efficacy can be
extrapolated from adult data along with comparisons of aripiprazole
pharmacokinetic parameters in adult and pediatric patients.
14.2 Bipolar Disorder
Monotherapy
Adults
The efficacy of ABILIFY in the acute treatment of manic episodes was
established in four 3-week, placebo-controlled trials in hospitalized patients
who met the DSM-IV criteria for bipolar I disorder with manic or mixed episodes.
These studies included patients with or without psychotic features and two of
the studies also included patients with or without a rapid-cycling course.
The primary instrument used for assessing manic symptoms was the Young Mania
Rating Scale (Y-MRS), an 11-li clinician-rated scale traditionally used to
assess the degree of manic symptomatology (irritability, disruptive/aggressive
behavior, sleep, elevated mood, speech, increased activity, sexual interest,
language/thought disorder, thought content, appearance, and insight) in a range
from 0 (no manic features) to 60 (maximum score). A key secondary instrument
included the Clinical Global Impression - Bipolar (CGI-BP) Scale.
In the four positive, 3-week, placebo-controlled trials (n=268; n=248; n=480;
n=485) which evaluated ABILIFY in a range of 15 mg to 30 mg, once daily (with a
starting dose of 15 mg/day in two studies and 30 mg/day in two studies), ABILIFY
was superior to placebo in the reduction of Y-MRS total score and CGI-BP
Severity of Illness score (mania). In the two studies with a starting dose of 15
mg/day, 48% and 44% of patients were on 15 mg/day at endpoint. In the two
studies with a starting dose of 30 mg/day, 86% and 85% of patients were on 30
mg/day at endpoint.
A trial was conducted in patients meeting DSM-IV criteria for bipolar I
disorder with a recent manic or mixed episode who had been stabilized on
open-label ABILIFY and who had maintained a clinical response for at least 6
weeks. The first phase of this trial was an open-label stabilization period in
which inpatients and outpatients were clinically stabilized and then maintained
on open-label ABILIFY (15 mg/day or 30 mg/day, with a starting dose of 30
mg/day) for at least 6 consecutive weeks. One hundred sixty-one outpatients were
then randomized in a double-blind fashion, to either the same dose of ABILIFY
they were on at the end of the stabilization and maintenance period or placebo
and were then monitored for manic or depressive relapse. During the
randomization phase, ABILIFY was superior to placebo on time to the number of
combined affective relapses (manic plus depressive), the primary outcome measure
for this study. The majority of these relapses were due to manic rather than
depressive symptoms. There is insufficient data to know whether ABILIFY is
effective in delaying the time to occurrence of depression in patients with
bipolar I disorder.
An examination of population subgroups did not reveal any clear evidence of
differential responsiveness on the basis of age and gender; however, there were
insufficient numbers of patients in each of the ethnic groups to adequately
assess inter-group differences.
Pediatric Patients
The efficacy of ABILIFY in the treatment of bipolar I disorder in pediatric
patients (10 to 17 years of age) was evaluated in one four-week
placebo-controlled trial (n=296) of outpatients who met DSM-IV criteria for
bipolar I disorder manic or mixed episodes with or without psychotic features
and had a Y-MRS score ≥20 at baseline. This double-blind, placebo-controlled
trial compared two fixed doses of ABILIFY (10 mg/day or 30 mg/day) to placebo.
The ABILIFY dose was started at 2 mg/day, which was titrated to 5 mg/day after 2
days, and to the target dose in 5 days in the 10 mg/day treatment arm and in 13
days in the 30 mg/day treatment arm. Both doses of ABILIFY were superior to
placebo in change from baseline to week 4 on the Y-MRS total score. Although
maintenance efficacy in pediatric patients has not been systematically
evaluated, maintenance efficacy can be extrapolated from adult data along with
comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric
patients.
Adjunctive Therapy
The efficacy of adjunctive ABILIFY with concomitant lithium or valproate in
the treatment of manic or mixed episodes was established in a 6-week,
placebo-controlled study (n=384) with a 2-week lead-in mood stabilizer
monotherapy phase in adult patients who met DSM-IV criteria for bipolar I
disorder. This study included patients with manic or mixed episodes and with or
without psychotic features.
Patients were initiated on open-label lithium (0.6 mEq/L to 1.0 mEq/L) or
valproate (50 µg/mL to 125 µg/mL) at therapeutic serum levels, and remained on
stable doses for 2 weeks. At the end of 2 weeks, patients demonstrating
inadequate response (Y-MRS total score ≥16 and ≤25% improvement on the Y-MRS
total score) to lithium or valproate were randomized to receive either
aripiprazole (15 mg/day or an increase to 30 mg/day as early as day 7) or
placebo as adjunctive therapy with open-label lithium or valproate. In the
6-week placebo-controlled phase, adjunctive ABILIFY starting at 15 mg/day with
concomitant lithium or valproate (in a therapeutic range of 0.6 mEq/L to 1.0
mEq/L or 50 µg/mL to 125 µg/mL, respectively) was superior to lithium or
valproate with adjunctive placebo in the reduction of the Y-MRS total score and
CGI-BP Severity of Illness score (mania). Seventy-one percent of the patients
coadministered valproate and 62% of the patients coadministered lithium were on
15 mg/day at 6-week endpoint.
Although the efficacy of adjunctive ABILIFY with concomitant lithium or
valproate in the treatment of manic or mixed episodes in pediatric patients has
not been systematically evaluated, such efficacy can be extrapolated from adult
data along with comparisons of aripiprazole pharmacokinetic parameters in adult
and pediatric patients.
14.3 Adjunctive Treatment of Major Depressive Disorder
Adults
The efficacy of ABILIFY (aripiprazole) in the adjunctive treatment of major
depressive disorder (MDD) was demonstrated in two short-term (6-week),
placebo-controlled trials of adult patients meeting DSM-IV criteria for MDD who
had had an inadequate response to prior antidepressant therapy (1 to 3 courses)
in the current episode and who had also demonstrated an inadequate response to 8
weeks of prospective antidepressant therapy (paroxetine controlled-release,
venlafaxine extended-release, fluoxetine, escitalopram, or sertraline).
Inadequate response for prospective treatment was defined as less than 50%
improvement on the 17-li version of the Hamilton Depression Rating Scale
(HAMD17), minimal HAMD17 score of 14, and a Clinical Global Impressions
Improvement rating of no better than minimal improvement. Inadequate response to
prior treatment was defined as less than 50% improvement as perceived by the
patient after a minimum of 6 weeks of antidepressant therapy at or above the
minimal effective dose.
The primary instrument used for assessing depressive symptoms was the
Montgomery-Asberg Depression Rating Scale (MADRS), a 10-li clinician-rated
scale used to assess the degree of depressive symptomatology (apparent sadness,
reported sadness, inner tension, reduced sleep, reduced appetite, concentration
difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal
thoughts). The key secondary instrument was the Sheehan Disability Scale (SDS),
a 3-li self-rated instrument used to assess the impact of depression on three
domains of functioning (work/school, social life, and family life) with each
li scored from 0 (not at all) to 10 (extreme).
In the two trials (n=381, n=362), ABILIFY was superior to placebo in reducing
mean MADRS total scores. In one study, ABILIFY was also superior to placebo in
reducing the mean SDS score.
In both trials, patients received ABILIFY adjunctive to antidepressants at a
dose of 5 mg/day. Based on tolerability and efficacy, doses could be adjusted by
5 mg increments, one week apart. Allowable doses were: 2 mg/day, 5 mg/day, 10
mg/day, 15 mg/day, and for patients who were not on potent CYP2D6 inhibitors
fluoxetine and paroxetine, 20 mg/day. The mean final dose at the end point for
the two trials was 10.7 mg/day and 11.4 mg/day.
An examination of population subgroups did not reveal evidence of
differential response based on age, choice of prospective antidepressant, or
race. With regard to gender, a smaller mean reduction on the MADRS total score
was seen in males than in females.
14.4 Irritability Associated with Autistic Disorder
Pediatric Patients
The efficacy of ABILIFY (aripiprazole) in the treatment of irritability
associated with autistic disorder was established in two 8-week,
placebo-controlled trials in pediatric patients (6 to 17 years of age) who met
the DSM-IV criteria for autistic disorder and demonstrated behaviors such as
tantrums, aggression, self-injurious behavior, or a combination of these
problems. Over 75% of these subjects were under 13 years of age.
Efficacy was evaluated using two assessment scales: the Aberrant Behavior
Checkul (ABC) and the Clinical Global Impression-Improvement (CGI-I) scale.
The primary outcome measure in both trials was the change from baseline to
endpoint in the Irritability subscale of the ABC (ABC-I). The ABC-I subscale
measured the emotional and behavioral symptoms of irritability in autistic
disorder, including aggression towards others, deliberate self-injuriousness,
temper tantrums, and quickly changing moods.
The results of these trials are as follows:
In one of the 8-week, placebo-controlled trials, children and adolescents
with autistic disorder (n=98), aged 6 to 17 years, received daily doses of
placebo or ABILIFY 2 mg/day to 15 mg/day. ABILIFY, starting at 2 mg/day with
increases allowed up to 15 mg/day based on clinical response, significantly
improved scores on the ABC-I subscale and on the CGI-I scale compared with
placebo. The mean daily dose of ABILIFY at the end of 8-week treatment was 8.6
mg/day.
In the other 8-week, placebo-controlled trial in children and adolescents
with autistic disorder (n=218), aged 6 to 17 years, three fixed doses of ABILIFY
(5 mg/day, 10 mg/day, or 15 mg/day) were compared to placebo. ABILIFY dosing
started at 2 mg/day and was increased to 5 mg/day after one week. After a second
week, it was increased to 10 mg/day for patients in the 10 mg and 15 mg dose
arms, and after a third week, it was increased to 15 mg/day in the 15 mg/day
treatment arm. All three doses of ABILIFY significantly improved scores on the
ABC-I subscale compared with placebo.
14.5 Agitation Associated with Schizophrenia or Bipolar
Mania
The efficacy of intramuscular aripiprazole for injection for the
treatment of agitation was established in three short-term (24-hour),
placebo-controlled trials in agitated inpatients from two diagnostic groups:
schizophrenia and bipolar I disorder (manic or mixed episodes, with or without
psychotic features). Each of the trials included a single active comparator
treatment arm of either haloperidol injection (schizophrenia studies) or
lorazepam injection (bipolar mania study). Patients could receive up to three
injections during the 24-hour treatment periods; however, patients could not
receive the second injection until after the initial 2-hour period when the
primary efficacy measure was assessed. Patients enrolled in the trials needed to
be: (1) judged by the clinical investigators as clinically agitated and
clinically appropriate candidates for treatment with intramuscular medication,
and (2) exhibiting a level of agitation that met or exceeded a threshold score
of ≥15 on the five lis comprising the Positive and Negative Syndrome Scale
(PANSS) Excited Component (ie, poor impulse control, tension, hostility,
uncooperativeness, and exclient lis) with at least two individual li
scores ≥4 using a 1-7 scoring system (1 = absent, 4 = moderate, 7 = extreme). In
the studies, the mean baseline PANSS Excited Component score was 19, with scores
ranging from 15 to 34 (out of a maximum score of 35), thus suggesting
predominantly moderate levels of agitation with some patients experiencing mild
or severe levels of agitation. The primary efficacy measure used for assessing
agitation signs and symptoms in these trials was the change from baseline in the
PANSS Excited Component at 2 hours post-injection. A key secondary measure was
the Clinical Global Impression of Improvement (CGI-I) Scale. The results of the
trials follow:
In a placebo-controlled trial in agitated inpatients predominantly meeting
DSM-IV criteria for schizophrenia (n=350), four fixed aripiprazole injection
doses of 1 mg, 5.25 mg, 9.75 mg, and 15 mg were evaluated. At 2 hours
post-injection, the 5.25 mg, 9.75 mg, and 15 mg doses were statistically
superior to placebo in the PANSS Excited Component and on the CGI-I
Scale.
In a second placebo-controlled trial in agitated inpatients predominantly
meeting DSM-IV criteria for schizophrenia (n=445), one fixed aripiprazole
injection dose of 9.75 mg was evaluated. At 2 hours post-injection, aripiprazole
for injection was statistically superior to placebo in the PANSS Excited
Component and on the CGI-I Scale.
In a placebo-controlled trial in agitated inpatients meeting DSM-IV criteria
for bipolar I disorder (manic or mixed) (n=291), two fixed aripiprazole
injection doses of 9.75 mg and 15 mg were evaluated. At 2 hours post-injection,
both doses were statistically superior to placebo in the PANSS Excited
Component.
Examination of population subsets (age, race, and gender) did not reveal any
differential responsiveness on the basis of these subgroupings.
How Supplied
16.1 How Supplied
ABILIFY® (aripiprazole) Tablets have
markings on one side and are available in the strengths and packages uled in
Table 15.
Table 15: ABILIFY Tablet Presentations
TabletStrength |
TabletColor/Shape |
TabletMarkings |
PackSize |
NDCCode |
2 mg
|
greenmodified rectangle |
"A-006"and "2" |
Bottle of 30
|
59148-006-13
|
5 mg
|
bluemodified rectangle |
"A-007"and "5" |
Bottle of 30Buler of 100 |
59148-007-1359148-007-35 |
10 mg
|
pinkmodified rectangle |
"A-008"and "10" |
Bottle of 30Buler of 100 |
59148-008-1359148-008-35 |
15 mg
|
yellowround |
"A-009"and "15" |
Bottle of 30Buler of 100 |
59148-009-1359148-009-35 |
20 mg
|
whiteround |
"A-010"and "20" |
Bottle of 30Buler of 100 |
59148-010-1359148-010-35 |
30 mg
|
pinkround |
"A-011"and "30" |
Bottle of 30Buler of 100 |
59148-011-1359148-011-35 |
ABILIFY DISCMELT® (aripiprazole) Orally Disintegrating
Tablets are round tablets with markings on either side. ABILIFY DISCMELT is
available in the strengths and packages uled in Table 16.
Table 16: ABILIFY DISCMELT Orally Disintegrating Tablet
Presentations
TabletStrength |
TabletColor |
TabletMarkings |
PackSize |
NDCCode |
10 mg
|
pink (withscattered specks) |
"A" and "640""10" |
Buler of 30 |
59148-640-23 |
15 mg
|
yellow (withscattered specks) |
"A" and "641""15" |
Buler of 30 |
59148-641-23 |
ABILIFY® (aripiprazole) Oral Solution (1 mg/mL) is
supplied in child-resistant bottles along with a calibrated oral dosing cup.
ABILIFY Oral Solution is available as follows:
 150 mL bottle NDC 59148-013-15
ABILIFY® (aripiprazole) Injection for intramuscular
use is available as a ready-to-use, 9.75 mg/1.3 mL (7.5 mg/mL) solution in
clear, Type 1 glass vials as follows:
 9.75 mg/1.3 mL single-dose vial NDC 59148-016-65
16.2 Storage
Tablets
Store at 25° C (77° F); excursions permitted between 15° C to 30° C (59° F to
86° F) [see USP Controlled Room Temperature].
Oral Solution
Store at 25° C (77° F); excursions permitted between 15° C to 30° C (59° F to
86° F) [see USP Controlled Room Temperature]. Opened bottles of ABILIFY Oral
Solution can be used for up to 6 months after opening, but not beyond the
expiration date on the bottle. The bottle and its contents should be discarded
after the expiration date.
Injection
Store at 25° C (77° F); excursions permitted between 15° C to 30° C (59° F to
86° F) [see USP Controlled Room Temperature]. Protect from light by storing in
the original container. Retain in carton until time of use.
Patient Counseling Information
17.1Â Â Â Information for Patients
Physicians are advised to discuss the following
issues with patients for whom they prescribe ABILIFY:
Increased Mortality in Elderly Patients with
Dementia-Related Psychosis
Patients and caregivers should be advised that elderly patients with
dementia-related psychoses treated with antipsychotic drugs are at increased
risk of death. ABILIFY is not approved for elderly patients with
dementia-related psychosis [see WARNINGS AND PRECAUTIONS (5.1)].
Clinical Worsening of Depression and Suicide Risk
Patients, their families, and their caregivers should be encouraged to be
alert to the emergence of anxiety, agitation, panic attacks, insomnia,
irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor
restlessness), hypomania, mania, other unusual changes in behavior, worsening of
depression, and suicidal ideation, especially early during antidepressant
treatment and when the dose is adjusted up or down. Families and caregivers of
patients should be advised to look for the emergence of such symptoms on a
day-to-day basis, since changes may be abrupt. Such symptoms should be reported
to the patient's prescriber or health professional, especially if they are
severe, abrupt in onset, or were not part of the patient's presenting symptoms.
Symptoms such as these may be associated with an increased risk for suicidal
thinking and behavior and indicate a need for very close monitoring and possibly
changes in the medication [see WARNINGS AND PRECAUTIONS (5.2)].
Prescribers or other health professionals should inform patients, their
families, and their caregivers about the benefits and risks associated with
treatment with ABILIFY and should counsel them in its appropriate use. A patient
Medication Guide about “Antidepressant Medicines, Depression and other Serious
Mental Illness, and Suicidal Thoughts or Actions” is available for ABILIFY. The
prescriber or health professional should instruct patients, their families, and
their caregivers to read the Medication Guide and should assist them in
understanding its contents. Patients should be given the opportunity to discuss
the contents of the Medication Guide and to obtain answers to any questions they
may have. It should be noted that ABILIFY is not approved as a single agent for
treatment of depression and has not been evaluated in pediatric major depressive
disorder.
Use of Orally Disintegrating Tablet
Do not open the buler until ready to administer. For single tablet removal,
open the package and peel back the foil on the buler to expose the tablet. Do
not push the tablet through the foil because this could damage the tablet.
Immediately upon opening the buler, using dry hands, remove the tablet and
place the entire ABILIFY DISCMELT Orally Disintegrating Tablet on the tongue.
Tablet disintegration occurs rapidly in saliva. It is recommended that ABILIFY
DISCMELT be taken without liquid. However, if needed, it can be taken with
liquid. Do not attempt to split the tablet.
Interference with Cognitive and Motor Performance
Because aripiprazole may have the potential to impair judgment, thinking, or
motor skills, patients should be cautioned about operating hazardous machinery,
including automobiles, until they are reasonably certain that aripiprazole
therapy does not affect them adversely [see WARNINGS AND
PRECAUTIONS (5.9)].
Pregnancy
Patients should be advised to notify their physician if they become pregnant
or intend to become pregnant during therapy with ABILIFY [see USE IN SPECIFIC POPULATIONS (8.1)].
Nursing
Patients should be advised not to breast-feed an infant if they are taking
ABILIFY [see USE IN SPECIFIC POPULATIONS (8.3)].
Concomitant Medication
Patients should be advised to inform their physicians if they are taking, or
plan to take, any prescription or over-the-counter drugs, since there is a
potential for interactions [see DRUG INTERACTIONS (7)].
Alcohol
Patients should be advised to avoid alcohol while taking ABILIFY [see DRUG INTERACTIONS (7.2)].
Heat Exposure and Dehydration
Patients should be advised regarding appropriate care in avoiding overheating
and dehydration [see WARNINGS AND PRECAUTIONS (5.10)].
Sugar Content
Patients should be advised that each mL of ABILIFY Oral Solution contains 400
mg of sucrose and 200 mg of fructose.
Phenylketonurics
Phenylalanine is a component of aspartame. Each ABILIFY DISCMELT Orally
Disintegrating Tablet contains the following amounts: 10 mg - 1.12 mg
phenylalanine and 15 mg - 1.68 mg phenylalanine.
Tablets manufactured by Otsuka Pharmaceutical Co, Ltd, Tokyo, 101-8535 Japan
or Bristol-Myers Squibb Company, Princeton, NJ 08543 USA
Orally Disintegrating Tablets, Oral Solution, and Injection manufactured by
Bristol-Myers Squibb Company, Princeton, NJ 08543 USA
Distributed and marketed by Otsuka America Pharmaceutical, Inc, Rockville, MD
20850 USA
Marketed by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA
US Patent Nos: 5,006,528; 6,977,257; and 7,115,587
ABILIFY is a trademark of Otsuka Pharmaceutical Company.
1239550A7 0309L-2745 Rev November 2009
© 2009, Otsuka Pharmaceutical Co, Ltd, Tokyo, 101-8535 Japan
MEDICATION GUIDE
ABILIFY
®
(a
BIL Ä fÄ«)
Generic name: aripiprazole
Antidepressant Medicines, Depression and other Serious
Mental Illnesses, and Suicidal Thoughts or Actions
Read the Medication Guide that comes with your or your family member’s
antidepressant medicine. This Medication Guide is only about the risk of
suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider
about:
- all risks and benefits of treatment with antidepressant medicines
- all treatment choices for depression or other serious mental
illness
What is the most important information I should know about
antidepressant medicines, depression and other serious mental illnesses, and
suicidal thoughts or actions?
-
Antidepressant medicines may increase suicidal thoughts or
actions in some children, teenagers, and young adults within the first few
months of treatment.
-
Depression and other serious mental illnesses are the most
important causes of suicidal thoughts and actions. Some people may have a
particularly high risk of having suicidal thoughts or actions. These
include people who have (or have a family history of) bipolar illness (also
called manic-depressive illness) or suicidal thoughts or actions.
-
How can I watch for and try to prevent suicidal thoughts
and actions in myself or a family member?
- Pay close attention to any changes, especially sudden changes, in mood,
behaviors, thoughts, or feelings. This is very important when an antidepressant
medicine is started or when the dose is changed.
- Call the healthcare provider right away to report new or sudden changes in
mood, behavior, thoughts, or feelings.
- Keep all follow-up visits with the healthcare provider as scheduled. Call
the healthcare provider between visits as needed, especially if you have
concerns about symptoms.
Call a healthcare provider right away if you or your family
member has any of the following symptoms, especially if they are new, worse, or
worry you:
- thoughts about suicide or dying
- attempts to commit suicide
- new or worse depression
- new or worse anxiety
- feeling very agitated or restless
- panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- other unusual changes in behavior or mood
What else do I need to know about antidepressant
medicines?
-
Never stop an antidepressant medicine without first talking
to a healthcare provider. Stopping an antidepressant medicine suddenly
can cause other symptoms.
-
Antidepressants are medicines used to treat depression and
other illnesses. It is important to discuss all the risks of treating
depression and also the risks of not treating it.
Patients and their families or other caregivers should discuss all treatment
choices with the healthcare provider, not just the use of antidepressants.
-
Antidepressant medicines have other side effects.
Talk to the healthcare provider about the side effects of the medicine
prescribed for you or your family member.
-
Antidepressant medicines can interact with other
medicines. Know all of the medicines that you or your family member
takes. Keep a ul of all medicines to show the healthcare provider. Do not
start new medicines without first checking with your healthcare provider.
-
Not all antidepressant medicines prescribed for children
are FDA approved for use in children. Talk to your child’s healthcare
provider for more information.
This Medication Guide has been approved by the U.S. Food and Drug
Administration for all antidepressants.
It should be noted that ABILIFY is approved to be added to an antidepressant
when the response from the antidepressant alone is not adequate. ABILIFY is not
approved for pediatric patients with depression.
Call your doctor for medical advice about side effects. You may report side
effects to FDA at 1-800-FDA-1088.
ABILIFY is a trademark of Otsuka Pharmaceutical Company.
1239550A7 0309L-2745C Rev November 2009
© 2009, Otsuka Pharmaceutical Co, Ltd, Tokyo, 101-8535 Japan
Package Label.principal Display Panel Section
DRUG: ABILIFYGENERIC: ABILIFYDOSAGE: TABLETADMINSTRATION: ORALNDC: 24236-792-23STRENGTH:30 mgCOLOR: pinkSHAPE: ROUNDSCORE: No scoreSIZE: 9 mmIMPRINT: A;011;30QTY: 180
Package Label.principal Display Panel
DRUG: ABILIFY
GENERIC: ABILIFY
>DOSAGE: TABLET
ADMINSTRATION: ORAL
NDC: 24236-792-02
STRENGTH:30 mg
COLOR: pink
SHAPE: ROUND
SCORE: No score
SIZE: 9 mm
IMPRINT: A;011;30
QTY: 30
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site